science pharmaceutical expo biotech jobs
Originally published online as doi:10.1189/jlb.0603252 on October 2, 2003

Published online before print October 2, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0603252v1
75/2/163    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroder, K.
Right arrow Articles by Hume, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroder, K.
Right arrow Articles by Hume, D. A.
(Journal of Leukocyte Biology. 2004;75:163-189.)
© 2004 by Society for Leukocyte Biology

Interferon-{gamma}: an overview of signals, mechanisms and functions

Kate Schroder*,{dagger}, Paul J. Hertzog{dagger},{ddagger}, Timothy Ravasi*,{dagger} and David A. Hume*,{dagger},1

* Institute for Molecular Bioscience, University of Queensland, St. Lucia, Brisbane, Australia;
{dagger} CRC for Chronic Inflammatory Diseases, Parkville, Victoria, Australia; and
{ddagger} Molecular Genetics Group, Institute of Reproduction and Development, Monash Medical Centre, Monash University, Clayton, Victoria, Australia

1 Correspondence: Institute for Molecular Bioscience, University of Queensland, St. Lucia, Brisbane 4072, Australia. E-mail: D.Hume{at}imb.uq.edu.au


arrow
ABSTRACT
 
Interferon-{gamma} (IFN-{gamma}) coordinates a diverse array of cellular programs through transcriptional regulation of immunologically relevant genes. This article reviews the current understanding of IFN-{gamma} ligand, receptor, signal transduction, and cellular effects with a focus on macrophage responses and to a lesser extent, responses from other cell types that influence macrophage function during infection. The current model for IFN-{gamma} signal transduction is discussed, as well as signal regulation and factors conferring signal specificity. Cellular effects of IFN-{gamma} are described, including up-regulation of pathogen recognition, antigen processing and presentation, the antiviral state, inhibition of cellular proliferation and effects on apoptosis, activation of microbicidal effector functions, immunomodulation, and leukocyte trafficking. In addition, integration of signaling and response with other cytokines and pathogen-associated molecular patterns, such as tumor necrosis factor-{alpha}, interleukin-4, type I IFNs, and lipopolysaccharide are discussed.

Key Words: macrophage • cytokine • lipopolysaccharide • Toll-like receptor • inflammation


arrow
INTRODUCTION
 
This review focuses on the interplay between interferon-{gamma} (IFN-{gamma}) and macrophages in inflammation and acquired immunity during infection. Macrophages are extremely versatile cells involved in a number of complex functions in disease and health. A pathogen encounters macrophages soon after host entry, and the result of these encounters is fundamental to the host’s ability to mount an effective immune response. Macrophage "activation", broadly defined as "acquisition of competence to execute a complex function" [1 ], is among the first actions to occur in innate immunity to potential pathogens. In most situations, macrophages are activated to acquire microbicidal effector functions and secrete proinflammatory cytokines, resulting in inflammation and recruitment of immune cells and subsequent elimination of the microbe by phagocytosis or release of toxic metabolites.

Macrophages respond to a range of different cell products during the innate and acquired immune response. Of these, IFN-{gamma} (originally called macrophage-activating factor) is among the most important. Macrophage stimulation with IFN-{gamma} induces direct antimicrobial and antitumor mechanisms as well as up-regulating antigen processing and presentation pathways. IFN-{gamma} orchestrates leukocyte attraction and directs growth, maturation, and differentiation of many cell types [2 3 4 ], in addition to enhancing natural killer (NK) cell activity [5 ] and regulating B cell functions such as immunoglobulin (Ig) production and class switching [4 , 6 ]. This review provides a brief overview of IFN-{gamma} biology with respect to the well-characterized responses that alter macrophage function during infectious challenge.


arrow
THE IFNs
 
The IFNs were originally discovered as agents that interfere with viral replication [7 ]. Initially, they were classified by the secreting cell type but are now classified into type I and type II according to receptor specificity and sequence homology. The type I IFNs are comprised of multiple IFN-{alpha} subtypes (14–20, depending on species), IFN-ß, IFN-{omega}, and IFN-{tau}, all of which are structurally related and bind to a common heterodimeric receptor (IFNAR, comprised of IFNAR1 and IFNAR2 chains). Although type I IFNs are secreted at low levels by almost all cell types, hematopoietic cells are the major producers of IFN-{alpha} and IFN-{omega}, whereas fibroblasts are a major cellular source of IFN-ß [8 ]. IFN-ß is also produced by macrophages under appropriate stimulus (discussed later). Viral infection is the classic stimulus for IFN-{alpha} and IFN-ß expression [8 , 9 ]. Secretion of IFN-{tau} has only been reported in ruminants [10 ].

IFN-{gamma} is the sole type II IFN. It is structurally unrelated to type I IFNs, binds to a different receptor, and is encoded by a separate chromosomal locus. Initially, it was believed that CD4+ T helper cell type 1 (Th1) lymphocytes, CD8+ cytotoxic lymphocytes, and NK cells exclusively produced IFN-{gamma} [8 , 11 ]. However, there is now evidence that other cells, such as B cells, NKT cells, and professional antigen-presenting cells (APCs) secrete IFN-{gamma} (reviewed in refs. [5 , 12 13 14 15 16 ]). IFN-{gamma} production by professional APCs [monocyte/macrophage, dendritic cells (DCs)] acting locally may be important in cell self-activation and activation of nearby cells [12 , 13 ]. IFN-{gamma} secretion by NK cells and possibly professional APCs is likely to be important in early host defense against infection, whereas T lymphocytes become the major source of IFN-{gamma} in the adaptive immune response [12 , 17 ].

IFN-{gamma} production is controlled by cytokines secreted by APCs, most notably interleukin (IL)-12 and IL-18. These cytokines serve as a bridge to link infection with IFN-{gamma} production in the innate immune response [18 19 20 21 22 23 24 ]. Macrophage recognition of many pathogens induces secretion of IL-12 and chemokines [e.g., macrophage-inflammatory protein-1{alpha} (MIP-1{alpha}); ref. 25 ]. These chemokines attract NK cells to the site of inflammation, and IL-12 promotes IFN-{gamma} synthesis in these cells [25 , 26 ]. In macrophages, NK and T cells, the combination of IL-12 and IL-18 stimulation further increases IFN-{gamma} production [20 , 23 , 24 , 27 , 28 ].

Negative regulators of IFN-{gamma} production include IL-4, IL-10, transforming growth factor-ß, and glucocorticoids [17 , 21 , 27 28 29 ]. Given the complexity of IFN-{gamma} regulation, it is not surprising that inbred mouse strains vary in their ability to secrete this cytokine; for example, T lymphocytes of C57BL/6 and C3H mice secrete significantly higher amounts of IFN-{gamma} compared with the T lymphocytes of BALB/c and B10.D2 mice. Increased IFN-{gamma} production in these strains is associated with greater resistance to bacteria and viruses [30 31 32 ]. Many excellent reviews on the regulation of IFN-{gamma} production have been published recently and the reader is referred to these for further information [11 12 13 ].


arrow
THE IFN-{gamma} RECEPTOR
 
Functional IFN-{gamma} receptor (IFNGR) is comprised of two ligand-binding IFNGR1 chains associated with two signal-transducing IFNGR2 chains and associated signaling machinery. IFNGR1 and IFNGR2 chains belong to the class II cytokine receptor family, a class of receptors that bind ligand in the small angle of a V formed by the two Ig-like folds that constitute the extracellular domain. It is likely that the IFNGR chains and other family members (type I IFN receptor and tissue factor) evolved from primitive adhesive molecules [33 , 34 ].

The IFNGR2 chain is generally the limiting factor in IFN-{gamma} responsiveness, as the IFNGR1 chain is usually in surplus [8 , 35 ]. The IFNGR2 chain is constitutively expressed, but its expression level may be tightly regulated according to the state of cellular differentiation or activation [8 ]. For example, some CD4+ Th1 populations have very low levels of cell-surface expression of the IFNGR2 chain and thus low expression of active IFNGR, leading to a functional blockade of some aspects of IFN-{gamma} signaling [36 , 37 ]. As the growth-inhibitory effects of IFN-{gamma} are blocked, T cells expressing low levels of the IFNGR2 chain continue to proliferate during IFN-{gamma} treatment. Conversely, IFN-{gamma} exposure to CD4+ Th2 populations displaying high levels of IFNGR2 inhibits proliferation and may induce the apoptotic program [35 , 38 , 39 ]. This mechanism may aid in the Th2-to-Th1 phenotype switch apparent when CD4+ cells are treated with IFN-{gamma}: the Th2 population decreases as a result of growth-inhibitory and proapoptotic effects of IFN-{gamma}, and the Th1 population continues to proliferate as a result of blockade of IFN-{gamma} function. As a consequence, IFN-{gamma} signaling causes IFNGR2 down-regulation and switching to a Th1 phenotype as a T cell population but not at a single-cell level [37 ].

Both IFNGR chains lack intrinsic kinase/phosphatase activity and so must associate with signaling machinery for signal transduction. The IFNGR1 intracellular domain contains binding motifs for the Janus tyrosine kinase (Jak)1 and the latent cytosolic factor, signal transducer and activator of transcription (Stat)1. In humans, the Jak1-binding motif LPKS is a membrane-proximal sequence located at residues 266–269 [40 41 42 ]. The human Stat1-binding site YDKPH is positioned at residues 440–444 [43 ]. This motif contains an essential Y440 phosphorylation site that is phosphorylated during signal transduction to allow Stat1 recruitment to the receptor [42 43 44 ]. Residues 441DKPH444 are responsible for the binding specificity of IFNGR1 and Stat1 [41 , 43 , 44 ]. The Jak1- and Stat1-binding motifs are required for receptor phosphorylation, signal transduction, and induction of biological response. Receptor-ligand internalization is mediated by an isoleucine-leucine sequence at residues 270 and 271 of the mature IFNGR1 chain in humans. Mutant receptors with deletion or substitution of this sequence cannot internalize ligand, although signal transduction is not affected [42 , 45 ].

The intracellular region of IFNGR2 contains a noncontiguous binding motif for recruitment of Jak2 kinase for participation in signal transduction. In humans, these sites are 263PPSIP267 and 270IEEYL274 [46 , 47 ]. The IFNGR2 chain is not tyrosine phosphorylated during signal transduction [46 ]. Cross-linking experiments with labeled human IFN-{gamma} demonstrated that IFN-{gamma} only associates with IFNGR2 when the IFNGR1 chain is present, indicating that the primary interaction between the IFNGR2 chain and the IFN-{gamma}:IFNGR1 complex is found between IFNGR1 and IFNGR2, although it is likely that IFNGR2 also interacts weakly with the ligand [46 , 48 ].

IFN-{gamma}:IFNGR1 and IFNGR1:IFNGR2 interactions are species-specific. A number of studies with chimeric receptors in which the intracellular, transmembrane, or extracellular domains were swapped between the human and murine IFNGR chains showed that species specificity in interactions of the ligand:receptor complex is restricted to the receptor extracellular domains [49 50 51 52 53 ].


arrow
IFN-{gamma} SYSTEM DYSFUNCTION
 
IFN-{gamma}-/- and IFNGR1-/- mice showed no overt developmental defects, and their immune system appeared to develop normally [54 ]. However, these mice show deficiencies in natural resistance to bacterial, parasitic, and viral infections such as vaccinia virus, Theiler’s murine encephalomyelitis virus, Leishmania major, Toxoplasma gondii, Listeria monocytogenes, and several poorly virulent mycobacteria species [54 55 56 57 58 59 ]. Some viruses (e.g., vaccinia virus, Theiler’s murine encephalomyelitis virus, and lymphocytic choriomeningitis virus) appear to require both type I and II IFN pathways, whereas viruses such as Semliki forest virus and vesicular stomatitis virus require a predominantly type I IFN response for efficient clearing [60 ]. These observations have prompted the suggestion that the two IFN systems may have evolved to complement each other in overlapping but nonredundant activities to defend against a broad spectrum of pathogens [60 , 61 ]. Historically, the type I IFNs were considered to be primarily antiviral agents with limited immunomodulatory activity, whereas IFN-{gamma} was considered to be primarily an immunomodulator with limited antiviral activity [8 ]. It is now apparent that both types of IFN possess antiviral and immunomodulatory activities to some degree [62 ]. The antiviral activity of both types of IFNs is often important in the early stages of viral infection, but their immunomodulatory activities become important in later stages of infection when the adaptive immune response becomes critical [60 ].

Patients with inactivating mutations of the human IFNGR1 or IFNGR2 chains show clinical presentation similar to the mouse models. Human loss-of-function mutations in the IFNGR1 or IFNGR2 chain are closely associated with severe susceptibility to poorly virulent mycobacteria, often presenting as early onset bacillus Calmette-Guerin infection and fatality in childhood [63 64 65 66 67 68 69 70 71 ]. Partial deficiency of either chain gives a milder phenotype and a much better prognosis [63 64 65 ]. Loss of functional IFNGR1 appears to be associated only with increased susceptibility to infection with some viruses and intracellular bacteria; increased susceptibility to other common bacterial and fungi pathogens have not been reported [72 ].

In addition to recurrent infection, infants with deficient production of IFN-{gamma} exhibited decreased neutrophil mobility and NK cell activity, highlighting the importance of IFN-{gamma} in the inflammatory response and immunoregulation [73 ]. It is interesting that natural IFN-{gamma} polymorphisms have been correlated with increased longevity [74 ]. It has been proposed that a slightly dampened inflammatory status caused by an IFN-{gamma} polymorphism, while not enough to significantly impact on the individual’s ability to clear infection, may prevent or defer inflammation-related diseases such as cardiovascular disease, neurodegeneration, osteoarthritis, osteoporosis, and diabetes [74 ].

Aside from functions in host defense, IFN-{gamma} may also contribute to autoimmune pathology. Although IFN-{gamma} production was shown to be disease-limiting in autoimmune models such as murine experimental allergic encephalomyelitis (EAE) [75 , 76 ], it may contribute to autoimmune nephritis [77 , 78 ]. In humans, IFN-{gamma} is implicated in pathology of diseases such as systemic lupus erythematosus [79 , 80 ], multiple sclerosis [81 ], and insulin-dependent diabetes mellitus [82 83 84 ].

IFN-{gamma} function is significant in tumor surveillance. IFNGR1 knockout (KO) mice, cells with dominant-negative IFNGR1 mutations, and cells treated with IFN-{gamma}-neutralizing antibodies display compromised tumor rejection [85 86 87 ]. IFN-{gamma} protects against tumor development and directs the immunogenic phenotype of tumors that arise in an immunocompetent host (the "cancer immunoediting" concept; reviewed in refs. [88 , 89 ]).


arrow
SIGNAL TRANSDUCTION
 
IFN-{gamma} primarily signals through the Jak-Stat pathway, a pathway used by over 50 cytokines, growth factors, and hormones to affect gene regulation [90 ]. Jak-Stat signaling involves sequential receptor recruitment and activation of members of the Janus family of kinases (Jaks: Jaks 1–3 and Tyk2) and the Stats (Stats 1–6, including Stat5a and Stat5b) to control transcription of target genes via specific response elements. As this signaling mechanism is a recurring theme amongst members of the cytokine receptor superfamily, IFN-{gamma}-induced Jak-Stat signaling has emerged as the global paradigm for class II cytokine receptor signal transduction.

The IFNGR1 and IFNGR2 subunits of the IFN-{gamma} receptor were thought not to strongly associate with each other in the absence of ligand [13 , 40 , 47 , 91 , 92 ], but new techniques allowing the study of receptor chain interactions in intact cells have shown the receptor complex is assembled before ligand binding [93 ]. Upon ligand binding, the intracellular domains of the receptor chains open out to allow association of downstream signaling components. Biologically active IFN-{gamma} is a noncovalent homodimer formed by the self-association of two mature polypeptides in an antiparallel orientation [94 , 95 ] and thus binds IFNGR1 in 2:2 binding stoichiometry [47 , 95 96 97 ]. Ligand binding induces Jak2 autophosphorylation and activation, which allows Jak1 transphosphorylation by Jak2 (Fig. 1 ) [98 ]. The activated Jak1 phosphorylates functionally critical tyrosines on residue 440 of each IFNGR1 chain to form two adjacent docking sites for the SH2 domains of latent Stat1 [41 , 99 100 101 ]. The receptor-recruited Stat1 pair is phosphorylated near the C terminus at Y701, probably by Jak2 [98 ]. Phosphorylation induces dissociation of a Stat1 homodimer (also known as {gamma}-IFN activation factor) from the receptor [100 ]. The four critical tyrosines (contained by Jak1, Jak2, IFNGR1, and Stat1) are phosphorylated within 1 min of IFN-{gamma} treatment [41 , 99 ].



View larger version (22K):
[in this window]
[in a new window]
  		Figure 1. The current paradigm for IFN-{gamma} signal transduction. Ligand binding causes a conformational change in the IFN-{gamma}R (IFNGR1, yellow; IFNGR2, green), such that the inactive Jak2 kinase undergoes autophosphorylation and activation, which in turn allows Jak1 transphosphorylation by Jak2. The activated Jak1 phosphorylates functionally critical tyrosines on residue 440 of each IFNGR1 chain to form two adjacent docking sites for the Src homology (SH)2 domains of latent Stat1. The receptor-recruited Stat1 pair is phosphorylated near the C terminus at Y701. Phosphorylation induces dissociation of a Stat1 homodimer from the receptor. To a lesser extent, IFN-{gamma} signaling also produces Stat1:Stat1:IFN regulatory factor (IRF)-9 and Stat1:Stat2:IRF-9 [IFN-stimulated gene factor 3 (ISGF3)] complexes. Stat1 homodimers travel to the nucleus and bind to promoter IFN-{gamma}-activation site (GAS) elements to initiate/suppress transcription of IFN-{gamma}-regulated genes. Many of IFN-{gamma}-regulated genes are in fact transcription factors (e.g., IRF-1), which are activated by IFN-{gamma} and are able to drive regulation of the next wave of transcription (e.g., induction of IFN-ß). Stat1:Stat1:IRF-9 heterodimers, ISGF3, and IRF-1 are able to bind to IFN-stimulated response element (ISRE) promoter regions in target genes to regulate transcription. IRF-1 is also able to promote transcription of Stat1 through an unusual ISRE site (IRF-E/GAS/IRF-E). Signaling molecules activated by IFN-{gamma} are depicted in red text. ICAM-1, Intercellular adhesion molecule-1; MIG, monokine induced by IFN-{gamma}; iNOS, inducible nitric oxide synthase.

The dissociated Stat1 homodimer enters the nucleus and binds to promoter elements to initiate or suppress transcription of IFN-{gamma}-regulated genes (reviewed in refs. [102 103 104 ]). Stat1 homodimers bind DNA at GAS elements of consensus sequence TTCN(2-4)GAA [105 ]. The key function of Stat1 in mediating IFN-{gamma} signal transduction is indicated by the phenotype of Stat1-/- mice, which largely phenocopy IFNGR1-/- mice during IFN-{gamma} stimulation [106 ].

The first wave of IFN-{gamma}-induced transcription occurs within 15–30 min of IFN-{gamma} treatment [107 ]. Many of the induced genes are in fact transcription factors (for example, IRF-1), which are activated by IFN-{gamma} and are able to further drive regulation of the next wave of transcription. Transcription of many IFN-{gamma}-responsive genes is controlled by a GAS element or an ISRE [108 ].


arrow
Stat1
 
The crystal structure for tyrosine phosphorylated Stat1 bound to DNA has been determined [109 ]. The structure verified that the SH2 domain necessary for dimerization is also involved in DNA binding. The C-terminal transactivation domain contains the Y701 phosphorylation site and also a S727 phosphorylation site, both of which are functionally important for efficient signaling [110 111 112 113 ]. All Stat proteins possess a SH2 domain that when tyrosine phosphorylated, mediates homodimerization or heterodimerization with other Stat molecules [114 , 115 ]. Although the simplistic model described above suggests that IFN-{gamma} signaling produces active Stat1 homodimers alone, other active complexes such as Stat1 heterodimers (e.g., Stat1:Stat2) and heterotrimers (e.g., Stat1:Stat1:IRF-9, Stat1:Stat2:IRF-9) form during signaling [102 , 116 117 118 ]. Stat2 is the only Stat that does not contain a DNA-binding domain [119 ]. The Stat1:Stat2:IRF-9 complex (known as ISGF3) was thought to be the typical type I IFN transcription factor. It is now evident that type I IFN signals primarily through ISGF3 but also uses Stat1 homodimers and conversely, type II IFN signals primarily through Stat1 homodimers but also uses ISGF3 to activate transcription [116 ]. This may explain many of the overlapping effects of the two types of IFNs.

Phosphorylation of Stat1 at S727 is essential for maximal ability to activate transcription of target genes [111 112 113 , 120 121 122 ]. A number of different stimuli induce Stat1 serine phosphorylation, including types I and II IFN, lipopolysaccharide (LPS), IL-2, IL-12, tumor necrosis factor {alpha} (TNF-{alpha}), and platelet-derived growth factor [110 111 112 , 123 , 124 ]. This may be a mechanism whereby S727 serves as an avenue for modulation of IFN-{gamma} signaling by independent extracellular cues. For example, LPS signaling increases Stat1 S727 phosphorylation independently of Y701 phosphorylation in macrophages, thereby augmenting cellular responses to IFN-{gamma} [110 ].

The ability of Stat1 to activate or repress gene transcription depends on the presence of other transcription factors binding to the promoter element and Stat1 interaction with other factors. Stat1 activation is necessary but not sufficient for transcription of a number of genes [125 , 126 ]. Likewise, factors such as oncostatin M, which participate in Jak-Stat signaling to produce activated Stat1, do not induce transcription of IFN-{gamma}-inducible genes [127 ]. Stat1 interaction with transcription factors such as IRF-9, upstream stimulatory factor-1, specificity protein-1, and heat shock factor-1 have been reported (reviewed in ref. [119 ]) and are likely to influence specificity of DNA binding and transactivator ability. Phosphorylation of S727 is necessary for interaction with some proteins, such as BRCA1 and MCM-5, and this interaction potentiates Stat1-mediated transcription [128 , 129 ]. In some promoters, transcription is maximal when more than one GAS-binding transcriptional activator binds to tandem GAS sites in the target gene promoter [130 , 131 ].

In the absence of IFN-induced tyrosine phosphorylation, Stat1 drives constitutive transcription of genes such as caspases [132 , 133 ]. The Stat1 KO mouse showed increased lymphocyte survival and proliferation, which was attributed to insufficient caspase levels to carry out the apoptotic program [133 ]. Stat1 also constitutively regulates expression of the low molecular protein 2 (LMP2) gene [134 ]. A complex of unphosphorylated Stat1 and IRF-1 may mediate this.

The mechanism of Stat1 entry into the nucleus is still controversial, but the involvement of importin-{alpha}-1 (NPI-1) is implied [135 ]. Two major models have been suggested, one being the classic nuclear importin mechanism and the other involving a requirement for intracellular IFN-{gamma}. Nuclear entry of Stat1 is apparent at 15 min and almost complete after 30 min exposure to IFN-{gamma} [136 ]. Stat1 nuclear translocation does not appear to be a result of liberation from a cytoplasmic anchor or transport by the cellular cytoskeleton or microtubules [136 ].

Experiments with green fluorescent protein-tagged Stat1 implied that it travels through the cytoplasm to the nucleus by random walk movement [136 ]. A model was proposed whereby Stat1 dimerization allows interaction with importin NPI-1, which then mediates translocation through the nuclear pore [135 ]. The nuclear membrane forms an efficient barrier to inactivated Stat1, and entry requires a gain of nuclear localization sequence (NLS) function [136 137 138 ]. To date, no "classic" NLS (single stretch of basic residues or bipartite motif; ref. [139 ]) has been identified for Stat1, indicating an as-yet unidentified, novel NLS is unmasked during Stat1 homodimerization, or the NLS of a Stat1 homodimer-binding partner mediates nuclear translocation.

The second model for Stat1 nuclear entry involves a requirement for intracellular IFN-{gamma}. IFN{gamma} enters the cell using a mechanism that is unclear at present. Nuclear accumulation of IFN-{gamma} is apparent shortly after cellular exposure to IFN-{gamma} [140 , 141 ]. Nuclear translocation is mediated by a C-terminal sequence very similar to the Simian virus-40 T antigen NLS, 126RKRKRSR132 in mice and 128KTGKRKR134 in humans [139 , 142 143 144 145 ]. This sequence is a functional NLS and is essential for the full biological activity of IFN-{gamma} [144 145 146 147 148 ]. A deletion mutant of the putative NLS in human IFN-{gamma} is still able to bind with high affinity to the IFNGR1 chain, but induction of biological response is absent [149 ]. The addition of a heterologous NLS is able to rescue biological responsiveness in this system. Another study tracked the cellular localization of components of the IFNGR complex following ligand exposure [150 ]. IFN-{gamma}, Stat1, and IFNGR1 were found to be quickly internalized, colocalized, and accumulated in the nucleus, while the majority of the IFNGR2 subunit remained at the cell surface throughout signaling. Stat1 nuclear translocation is mediated by NPI-1 [135 ], and immunoprecipitation of Stat1 following IFN-{gamma} treatment showed that IFN-{gamma}, IFNGR1, Stat1, and NPI-1 form a complex at the nuclear pore during translocation [142 , 143 ]. Subramaniam et al. [90 ] proposed a model suggesting a function for intracellular ligand in Stat1 nuclear localization. In this model, extracellular ligand binds to the IFNGR1 chain, causing endocytosis of the complex and recycling of the IFNGR2 chain to the cell surface. The intracellular domain of IFNGR1 associates with activated Stat1 and intracellular IFN-{gamma}, and the IFN{gamma}:IFNGR1:Stat1 complex is actively transported through the nuclear pore via IFN-{gamma}–NLS interaction with the NPI-1 importin. Activated Stat1 may then bind to promoter elements to activate transcription.

Functional Stat1 is crucial to host response to infection. KO of Stat1 renders mice extremely sensitive to infection by viral and microbial pathogens (e.g., vesicular stomatitis viruses, mouse herpes virus, L. monocytogenes) [106 , 151 ]. This susceptibility has been attributed to defective immune system function as a result of the combined loss of types I and II IFN responses [151 ]. NO production in Stat1-/- macrophages primed with types I or II IFN and treated with LPS is greatly impaired compared with the wild type (WT), resulting in reduced macrophage microbicidal function [106 ]. Impaired macrophage microbicidal function may contribute to the increased susceptibility to infection apparent in Stat1-/- mice.

Stat1 KO mice also demonstrated the existence of Stat1-independent mechanisms in IFN-{gamma} signaling. IFN-{gamma} may exert pro- and antiproliferative signals through Stat1-independent and Stat1-dependent pathways, respectively [152 153 154 ]. Although IFN-{gamma} treatment of lymphocytes and fibroblasts inhibited cell growth, the same treatment in Stat1-/- cells promoted proliferation and decreased apoptotic signals [133 , 153 , 154 ]. Microarray analysis revealed that many genes, including the growth-promoting c-myc and c-jun genes, were induced in response to IFN-{gamma} in Stat1-/- cells [152 ]. This signaling was not dependent on the Stat1-docking site of IFNGR1. Although much more susceptible than their WT counterparts, Stat1-/- mice are significantly more resistant to viral infection than IFNGR1/IFNAR1 double-KO mice, indicating the existence of IFN-dependent, Stat1-independent, antiviral mechanisms [155 ].

A loss-of-function, heterozygous mutation in the Stat1 gene was recently described in humans, resulting in a dominant-negative effect over the WT allele for Stat1 activation [156 ]. Although these patients demonstrated increased susceptibility to bacterial infection, viral infections took the normal clinical course. This suggests that IFN-{gamma}-induced, physiologically significant, Stat1-independent control of antiviral responses also occurs in humans.

Mechanisms of Stat1-independent IFN-{gamma} signaling are currently unclear. One possibility is the existence of an unknown IFN-{gamma} receptor or IFN-{gamma} receptor complex linked to an alternative signaling pathway. This hypothesis was suggested when it was found that anti-IFN-{gamma} antibodies affected the clinical course of EAE in IFNGR1 KO mice [75 ].


arrow
IRF-1
 
The IRF gene family is intimately involved in mediating the type I and II IFN signal cascades. Members of the IRF family share similar structure, including an amino-terminal DNA-binding domain containing multiple tryptophan residues and a carboxy-terminal transcriptional activation or repression domain (reviewed in ref. [157 ]). IRF-1, IRF-2, and IRF-9 (p48, ISGF3-{gamma}) all participate in IFN-{gamma} signaling. Basal IRF-1 expression has functions in constitutive gene expression [134 ], but Stat1 and nuclear factor (NF)-{kappa}B interaction with promoter elements dramatically increases IRF-1 transcription [158 159 160 ]. IRF-1 expression is up-regulated in response to types I and II IFN, virus, or cytokines. IRF-1 transcriptional regulatory activity is regulated independently in response to IFN-{gamma}, virus, and dsRNA [161 ]. The physiological relevance of IRF-1 function in transcriptional control of IFN-{gamma}-regulated genes is highlighted by IRF-1 KO mice, in which many genes are submaximally induced by IFN-{gamma} when compared with their WT littermates [162 , 163 ]. IRF-1 functions are not limited to IFN-{gamma} signaling; IFN-{gamma}-independent activities in viral/bacterial infection, lymphocyte development, regulation of cell cycle, growth inhibition, apoptosis and tumor suppression have been reported [107 , 123 , 135 , 159 , 164 165 166 167 168 ].

IRF-1 drives inducible expression of many target genes through interaction with the IRF-E site, consensus G(A)AAAG/CT/CGAAAG/CT/C [102 , 164 ]. This specificity overlaps with the ISRE consensus site A/GNGAAANNGAAACT, recognized by ISGF3, which is induced by type I IFN and to a lesser extent, type II IFN [102 ]. In this way, IRF-1 is able to induce a subset of the full spectrum of IFN-inducible genes. IRF-2 also binds to the IRF-E site and largely functions to repress transcription of IRF-1-inducible genes through its transcriptional repressor domain [102 , 159 ].

Negative regulation of IFN-{gamma} signaling
Stat1 activation is inhibited within 1 h of IFN-{gamma} treatment, despite the continued presence of extracellular IFN-{gamma}, and so mechanisms must exist to control the extent of ligand stimulation of IFN-{gamma} signaling (Fig. 2 ) [117 , 169 ]. These mechanisms involve every level of the pathway.



View larger version (29K):
[in this window]
[in a new window]
  		Figure 2. Negative regulation of IFN-{gamma} signaling. A number of factors limit the extent and duration of IFN-{gamma} signal transduction. Receptor IFNGR2 (green) expression is tightly regulated in some cell types, whereas IFNGR1 (yellow) surface concentration may be regulated by the extent of recycling following receptor:ligand internalization. Protein tyrosine phosphatases (PTPs), such as SH2-containing tyrosine phosphatase-2 (Shp2), dephosphorylate Jak1, Jak2, and IFNGR1, and suppressors of cytokine signaling-1 (SOCS-1) and SOCS-3 interfere with Jak activity to turn off signaling after ligand binding. Stat1 activation is down-regulated by Stat1 dephosphorylation in the nucleus. IRF-2 antagonizes transcriptional activation of many (IRF-1-inducible) genes containing ISRE or IRF-E promoter elements by competing for binding sites without promoting gene expression. Signaling molecules activated by IFN-{gamma} are depicted in red text.

Following signal transduction, the IFN-{gamma}:IFNGR1 complex internalizes and enters the endosomal pathway, where the complex dissociates [170 ]. In many cell types, the IFNGR1 chain eventually recycles to the cell surface in its uncoupled, dephosphorylated form, and the ligand is degraded [45 , 171 , 172 ]. In some cell types, IFN-{gamma} signaling may induce degradation of the internalized receptor, thereby down-regulating IFNGR1 surface expression [45 ]. This may be a mechanism by which these cells can prevent overstimulation of the pathway through cellular desensitization. Such a mechanism may also allow differential regulation of IFN-{gamma}-induced responses in different cell types [37 ].

One of the most inducible targets of IFN-{gamma} is a specific feedback inhibitor, SOCS-1, which associates with Jak1/2, interfering with tyrosine kinase activity and inhibiting downstream IFN-{gamma} signaling [173 174 175 176 177 ]. SOCS-1 may also promote degradation of signaling machinery by binding to and targeting signaling molecules for the ubiquitin-proteasome pathway [178 ]. Overexpression of SOCS-1 in cells in vitro or in transgenic mice causes loss of responsiveness to IFN-{gamma} [176 , 179 ]. Conversely, SOCS-1-/- mice are hyper-responsive to microbial infection, exhibit enhanced macrophage cytocidal activity, and die of IFN-{gamma}-dependent, multisystem inflammatory tissue destruction in the absence of infection [180 , 181 ]. This indicates that IFN-{gamma} is normally present and performs important functions in vivo, even in the absence of infection. Another SOCS protein, SOCS-3, is also induced by IFN-{gamma} and negatively regulates IFN-{gamma} signaling, although perhaps less effectively than SOCS-1 [182 ].

Aside from SOCS protein function, IFN-{gamma} signal down-regulation can occur by receptor and Jak dephosphorylation by the PTPs Shp1 and Shp2 [183 184 185 186 187 ]. Shp2 null cells exhibit elevated tyrosine phosphorylation and DNA-binding ability of Stat1 and show enhanced suppression of cell growth with IFN-{gamma} treatment [184 ]. Shp1 KO mice (motheaten mice, me/me) die from a condition caused by dysregulation of a large number of cytokines, possibly including IFN-{gamma} [188 ].

Stat1 phosphorylation may also be controlled by nuclear dephosphorylation. Stat1 homodimers enter the nucleus and are actively retained by a mechanism dependent on the kinase function of Jak1 [189 ]. McBride et al. [137 ] proposed a model in which nuclear export is mediated by a leucine-rich nuclear export signal (NES) at residues 197–205, which is hidden when Stat1 is bound to DNA. Stat1 dephosphorylation by a nuclear protein tyrosine phosphate (PTP) allows the release of DNA and subsequent recognition of the NES by chromosome region maintenance/exportin 1 (CRM1), an export receptor for NES-containing proteins [190 , 191 ]. CRM1 then mediates Stat1 translocation through the nuclear pore in a Ran-GTPase-dependent manner. This model is supported by work from other groups, demonstrating Stat1 tyrosine dephosphorylation in the nucleus and subsequent recycling of inactive Stat1 to the cytoplasm, and is consistent with the crystal structure of Stat1 bound to DNA [137 , 189 , 192 , 193 ].

Signaling specificity
The many cytokines that use Jak-Stat signaling direct transcription through specific but not necessarily unique combinations of Jaks and Stats. This raises the question of how signal specificity is maintained when many cytokines use the same signaling machinery.

Evidence for a devoted role of Jaks in signal transduction of specific cytokines is controversial. Mutant cell lines lacking Jak1 or Jak2 have demonstrated deficiency in types I and II IFN signaling (Jak1) or IFN-{gamma} signaling (Jak2) [194 , 195 ]. These deficiencies are reflected in the Jak1 and Jak2 KO mice, suggesting that these Jaks are functionally specific to their cytokine systems, and other Jaks cannot substitute for them in vivo. Jak1 gene KO mice exhibit a number of abnormalities, all attributable to signaling deficits in three cytokine receptor families: type II cytokine receptors (i.e., types I and II IFN and IL-10 receptors); all cytokines that use the {gamma}c subunit for signaling, thereby promoting lymphopoiesis (e.g., IL-2, IL-4, IL-7 receptors); and gp130 receptor family members (e.g., IL-6, IL-11, leukemia inhibitory factor receptors) [196 ]. These results showed that in vivo, the role of Jak1 is essential and nonredundant in signal transduction and induction of biological response for a specific range of cytokine receptors. Jak2 gene KO in mice is embryonic lethal as a result of deficiencies in erythropoiesis [197 , 198 ]. Other than suppression of IFN-{gamma} signaling, the cytokine response deficit of Jak2 KO mice is largely nonoverlapping compared with Jak1 KO mice [197 , 198 ]. This indicates that other Jaks cannot functionally substitute for Jak2 in vivo, although Jak3 can substitute for Jak2 in vitro to produce Stat1 homodimers and activate transcription of class I major histomcompatibility complex (MHC) [199 ].

Although specific Stats appear to be dedicated to specific subsets of cytokine signaling, the same Stat or combination of Stats can be activated in different cytokine systems to give completely different biological effects (e.g., IFN-{gamma} and oncostatin M as described earlier). Possible mechanisms giving rise to specificity of response with respect to Stats include: different thresholds/timeframes of Stat activation may be required for specific biological responses, and specific Stat complexes induced by cytokines may give different biological effects. It is widely agreed that signal specificity is largely conferred by the particular Stats activated in cytokine signaling [106 , 151 , 200 201 202 203 204 205 ]. This is supported by the Stat1 KO mouse, which displays loss of only IFN signaling, despite multiple reports of Stat1 activation in response to a range of other cytokines in vitro [106 , 151 ]. Similarly, KO mice of the other Stat proteins showed a loss of biological responsiveness to a single cytokine, indicating that Stat activation may be specific for a single cytokine in vivo if not in vitro [169 ]. In addition to the Stats themselves, other factors (e.g., intracellular IFN-{gamma} as described above, or cell-specific transcription factors), which associate with Stats may contribute to the specificity of the signal.

Cross-talk between IFN-{alpha}/ß and IFN-{gamma} pathways
The IFN-{gamma} and IFN-{alpha}/ß signal pathways cross-talk at multiple levels. The signal pathways and target genes used by types I and II IFN are partially overlapping, which gives the opportunity for cross-talk to synergize or antagonize particular functions within the cell. This cross-talk is biologically relevant, as cells in vivo are not stimulated with one cytokine in isolation, rather a cytokine cocktail instructs gene expression through the integration of multiple signaling pathways.

Although IFN-{gamma} primarily signals through Stat1 homodimers in the initial signal cascade, additional signaling molecules are activated. As noted above, the archetypal type I IFN signaling molecule ISGF3 is activated by IFN-{gamma}, thus providing a mechanism for cross-talk between the types I and II IFN pathways [116 ]. ISGF3 is able to induce expression of type I IFN, thereby further amplifying the response of IFN-{alpha}/ß-induced genes [206 , 207 ]. Conversely, type I IFN can elicit classic type II IFN signaling molecules such as active Stat1 homodimers, which are able to bind to GAS sites to activate transcription of target genes [17 , 208 ].

Takaoka et al. [209 ] published data indicating that IFN-{gamma} signaling in mouse embryonic fibroblasts requires a constitutive subthreshold IFN-{alpha}/ß signal. They have suggested that IFN-{alpha}/ß may promote the interaction of the IFNGR2 and IFNAR1 chains in the caveolar membrane domains of the cell membrane. In this model, low level IFN-{alpha}/ß signal is necessary for maintaining its receptor in the phosphorylated form, thus providing a functional aid for efficient assembly of IFN-{gamma}-activated Stat1 homodimers.


arrow
CELLULAR EFFECTS OF IFN-{gamma}
 
Class I antigen presentation pathway
Types I and II IFN up-regulate multiple functions within the class I antigen presentation pathway to increase the quantity and diversity of peptides presented on the cell surface in the context of class I MHC. Up-regulation of cell-surface class I MHC by IFN-{gamma} (Table 1 ) is important for host response to intracellular pathogens, as it increases the potential for cytotoxic T cell recognition of foreign peptides and thus promotes the induction of cell-mediated immunity.


View this table:
[in this window]
[in a new window]
  		Table 1. IFN-{gamma}-Regulated Genes and Their Function in Producing IFN-{gamma} Effects

IFN-{gamma} stimulation induces a replacement of the constitutive proteasome subunits with "immunoproteasome" subunits. In unstimulated cells, the proteasome enzymatic subunits are ß1, ß2, and ß5, encoded outside of the MHC locus. IFN-{gamma} induces expression of new subunits, LMP2, MECL-1, and LMP7, which competitively replace ß1, ß2, and ß5 subunits of the proteasome, respectively [210 211 212 213 214 215 216 ]. In this way, new species of proteasome are formed, consisting of LMP2:MECL-1:LMP7 (the immunoproteasome), LMP2:MECL-1:ß5, or ß1:ß2:LMP7, as well as low levels of the ß1:ß2:ß5 constitutive proteasome [216 ]. Inducible proteasome replacement is thought to be a mechanism by which IFN-{gamma} can increase the quantity, quality, and repertoire of peptides for class I MHC loading. The quantity is increased, as overall expression levels of proteasome are increased. The cleavage specificity of the immunoproteasome may allow production of peptides better able to bind class I MHC and thereby increase efficiency in the system. Peptide diversity is thought to increase as a result of differences in cleavage specificities between different species of proteasome. As a whole, this serves to increase levels and diversity of epitopes presented for CD8+ T cell recognition in the context of class I MHC and thus increase immune surveillance (reviewed in ref. [216 ]). This mechanism may have evolved to ensure LMP2/LMP7/MECL-1-dependent epitopes are only produced in sites of inflammation and thus avoid autoimmunity without compromising appropriate T cell stimulation [216 ].

The efficiency of peptide generation is further increased with the IFN-{gamma}-induced PA28, which is composed of PA28{alpha} and PA29ß subunits and associates with the proteasome and alters proteasome proteolytic cleavage preference. It is thought to gear antigen processing toward more efficient generation of TAP- and class I MHC-compatible peptides to increase overall efficiency of class I MHC peptide delivery [217 , 218 ].

The IFN-{gamma}-inducible TAP transporter is vital in peptide transport from the cytosol to the ER lumen [307 ]. TAP transiently associates with class I MHC to aid in efficient peptide loading [307 , 308 ]. Genes encoding the TAP subunits are located within the class II MHC locus and are coordinately expressed with MHC class I [220 , 221 ].

The class I MHC complex is composed of a heavy chain (consisting of {alpha}1, {alpha}2, and {alpha}3 domains) and a light chain (ß2microglobulin) and is up-regulated by IFN-{gamma} stimulation [4 , 222 , 224 225 226 227 228 229 230 231 232 ]. Chaperones such as tapasin and GP96 implicated in aiding in the efficient assembly of peptide:MHC I complexes are also up-regulated by IFN-{gamma} [4 , 309 , 310 ].

Class II antigen presentation pathway
Of the IFNs, IFN-{gamma} alone can efficiently up-regulate the class II antigen presenting pathway and thus promote peptide-specific activation of CD4+ T cells [4 , 234 ]. IFN-{gamma} treatment further up-regulates class II MHC molecules in cells constitutively expressing class II MHC, such as B cells, DCs, and cells of the monocyte-macrophage lineage (professional APCs) [234 ]. IFN-{gamma} is also able to induce class II MHC expression in cells that do not constitutively express these genes (nonprofessional APCs) [76 ]. IFN-{gamma} up-regulates the quantity of peptide:MHC II complexes on the cell surface by promoting expression of several key molecules (Table 1) : the Ii chain and the components of the class II MHC complex [234 235 236 237 238 239 ]; cathep sins B, H, and L, lysosomal proteases implicated in production of antigenic peptides for class II MHC loading [240 , 241 ]; and DM, a regulator of peptide accessibility to the peptide-binding cleft of class II MHC [235 , 237 ].

The CIITA mediates coordinate transcriptional control over these genes. Targeted disruption of CIITA in mice causes complete loss of constitutive or inducible display of class II MHC molecules [311 ]. Likewise, loss of constitutive/inducible class II MHC display is found in humans with CIITA mutation (Bare Lymphocyte Syndrome) [312 313 314 ]. As CIITA is the limiting factor in a complex that directs transcriptional regulation, it acts as a switch for rapid up-regulation of class II MHC-related genes by IFN-{gamma} [315 ].

IFN-{gamma} and development of Th1 response
IFN-{gamma} is a major product of Th1 cells and further skews the immune response toward a Th1 phenotype. IFN-{gamma} achieves this by promoting characteristic Th1 effector mechanisms: innate cell-mediated immunity (via activation of NK cell effector functions), specific cytotoxic immunity (via T cell:APC interactions), and macrophage activation (discussed below) [4 ]. IFN-{gamma}-induced, specific cytotoxic immunity is promoted by direct and indirect mechanisms. IFN-{gamma} promotes specific cytotoxic immunity by indirect mechanisms, such as growth inhibition of Th2 populations and up-regulation of antigen processing, presentation, and APC costimulatory molecules, thereby increasing CD4+ differentiation. IFN-{gamma} also influences naïve CD4+ cell differentiation toward a Th1 phenotype more directly. The phenotype adopted by a naive T cell during T cell activation is heavily influenced by the cytokine milieu present at the time of T cell receptor engagement. IFN-{gamma} and IL-12 are the prototypic cytokines directing Th1 differentiation during the primary response to antigen, and IL-4 directs differentiation of Th2 populations. IFN-{gamma} induces IL-12 production in phagocytes [296 ] and inhibits IL-4 secretion by Th2 populations [39 ], which may further drive Th1 differentiation in vivo.

IL-12 and IFN-{gamma} coordinate the link between pathogen recognition by innate immune cells and the induction of specific immunity, by mediating a positive feedback loop to amplify the Th1 response [4 ]. LPS and other pathogen-associated molecular patterns directly trigger IL-12 production upon recognition by macrophages, DCs, and neutrophils [316 317 318 319 ], which in turn induces IFN-{gamma} secretion in antigen-stimulated, naive CD4+ T cells and NK cells [320 , 321 ]. IL-12-induced IFN-{gamma} participates in positive feedback by further promoting IL-12 production in macrophages [296 , 297]. This amplification may be important in initiation or stabilization of the Th1 response (reviewed in refs. [4 , 322 ]). IL-18 is highly synergistic with IL-12 for IFN-{gamma} production and has important functions in the in vivo Th response [23 , 24 ].

Secretion of large amounts of IFN-{gamma} or IL-4 is the defining feature of Th1 or Th2 cells, respectively [323 ]. These cytokines function to directly promote cell-mediated immunity (IFN-{gamma}) or humoral immunity (IL-4) and to reciprocally antagonize each other’s actions, further polarizing the response (reviewed in ref. [108 ]). For example, IL-4 inhibits IFN-{gamma}-dependent activation of macrophage-effector functions [324 , 325 ]. Conversely, IFN-{gamma} antagonizes IL-4-dependent induction of the IgE receptor, Fc{varepsilon}RII [326 ].

The IFN-induced antiviral state
The IFN system regulates innate and adaptive immunity to viral infection. Viral invasion directly triggers induction of type I IFNs, through a mechanism involving IRF-3 and IRF-7 (reviewed in ref. [327 ]). Although both types of IFN are crucial in the immediate cellular response to viral infection, the immunomodulatory activities of IFN-{gamma} (discussed elsewhere) become important later in the response in coordinating the immune response and establishing an antiviral state for longer term control [54 , 60 , 328 , 329 ].

IFN-{gamma}-induced antiviral mechanisms include induction key antiviral enzymes (Table 1) , most notably PKR, which is a serine/threonine kinase greatly induced by types I and II IFN stimulation [242 , 330 ]. PKR is inactive in its constitutive form and requires an activating signal for autophosphorylation. dsRNA, a necessary intermediate in replication of RNA viruses, is the best characterized activator of PKR, although other agents such as heparin are able to activate PKR [331 ]. Association of PKR with dsRNA is likely to cause a conformational change that unmasks the catalytic domain responsible for PKR autophosphorylation [242 , 332 ]. PKR is then activated for dsRNA-independent phosphorylation of specific cellular substrates [333 ]. One of these substrates is the eIF-2{alpha} subunit, a rate-limiting factor in the normal cellular translational machinery. Phosphorylation by PKR prevents recycling of eIF-2–GTP from its guanosine 5'-diphosphate-bound form, thereby inhibiting viral and cellular protein synthesis [242 ]. PKR is implicated in numerous other functions, including activation of NF-{kappa}B [243 , 334 ], TNF-{alpha} transcript splice regulation [244 ], induction of fas-mediated apoptosis [245 , 246 ], and regulation of Stat1 activity [154 , 247 ].

It is likely that IFNs induce many as-yet undiscovered antiviral proteins, as the enzymes above and described in Table 1 do not account for all IFN-induced antiviral effects [335 , 336 ]. Also, the host of factors mediating the profound growth-inhibitory and proapoptotic effects of IFN-{gamma} would have no small part in limiting viral replication within the cell and spread to other cells.

Cell cycle, growth, and apoptosis
Macrophages are produced in large amounts by the bone marrow, and many die shortly after production by a process of programmed cell death ("apoptosis") [337 ]. After release from the bone marrow, macrophages proliferate, differentiate, acquire specialized functions (e.g., microbicidal activity), or die by apoptosis depending on the presence or absence of extracellular cues. Many reports indicate that IFN-{gamma} arrests the macrophage cell cycle and provides a survival signal, and others suggest that it serves as a proapoptotic signal. Although recent advances in cell cycle control and apoptosis have greatly increased our understanding in these functions in isolation, the inter-relationship between these intimately related processes is still somewhat confusing. For this reason, the effects of IFN-{gamma} on cellular proliferation and apoptosis are described here separately.

One of the most easily observed effects of IFN-{gamma} is cell growth inhibition. Types I and II IFN are able to protect against pathogen-induced apoptosis and suppress colony stimulating factor type 1 (CSF-1)-dependent growth of bone marrow-derived macrophages (BMM) [252 ]. Granulocyte macrophage-CSF, which is usually released by T cells at the same time as IFN-{gamma}, is able to protect against the growth-inhibitory effects of IFN-{gamma} on macrophages, and this may be physiologically important in vivo [338 ]. The IFNs most commonly arrest the cell cycle at the G1/S checkpoint, although blockages of other cell cycle stages have been reported [339 340 341 ]. It has been suggested that IFN-induced G1 arrest may actually reflect exit from the cell cycle into G0 [342 ].

IFNs inhibit proliferation primarily by increasing protein levels of Ink4 and Cip/Kip CKIs [252 253 254 255 , 343 , 344 ]. IFN-{gamma} transcriptionally induces p21 and p27 CKIs (Table 1) [256 , 345 , 346 ]. p21 and p27 inhibit the activity of cyclin E:CDK2 and cyclin D:CDK4 complexes, respectively, thereby arresting the cell cycle at the G1/S boundary. Decreased cyclin:CDK activity during G1 results in hypophosphorylation of the tumor suppressor Rb. In its hypophosphorylated state, Rb sequesters the E2F family of transcription factors from activation of genes (e.g., c-myc) required for cell cycle progression from G1 to S phase [292 ]. c-myc controls G1/S transition by activating cyclin:CDK complexes and inducing transcription of genes required for S phase (reviewed in ref. [263 ]). Expression of c-myc is induced rapidly by a number of growth factors and cytokines and is down-regulated by IFN-{gamma} [154 , 264 ]. IFN-{gamma} influences c-myc expression through multiple pathways, including suppression of Rb phosphorylation, resulting in decreased E2F activity as well as Rb-independent pathways, which may be a result of PKR action [251 ]. In its active form, c-myc is associated with max, and the myc:max heterodimer activates transcription of genes required for cell cycle progression [265 ]. The level of active myc is negatively regulated by mad1, which sequesters the max coactivator away from myc and suppresses transcription of myc-inducible genes [259 ]. In this way, the mad1-to-c-myc ratio determines whether a cell will proliferate (as a result of high levels of myc:max) or arrest in G1 (as a result of high levels of mad1:max) [259 , 260 ]. In addition to decreasing the abundance of myc, IFN-{gamma} increases mad1 levels, thereby further antagonizing myc activity and inhibiting CSF-1-dependent proliferation in BMM [347 ].

Apoptosis is a process in which the cell directs its own demise by activating intrinsic suicide machinery (reviewed in refs. [337 , 348 ]). In macrophages, apoptosis may be desirable to prevent colonization by intracellular pathogens. Conversely, many pathogens actually induce host-cell death through secretion of macrophage-specific toxins. Induction of apoptosis by signals such as DNA damage requires the IRF-1 tumor-suppressor gene [165 , 266 , 267 ]. Levels of IRF-1 may be a deciding factor in whether IFN-{gamma} induces or protects from apoptosis on treated cells [35 , 349 , 350 ]. It is proposed that IFN-{gamma} treatment of cells with high levels of functional IFNGR very rapidly activates Stat1, thereby producing high levels of IRF-1 that are able to induce apoptosis. In contrast, IFN-{gamma} treatment of cells with low levels of functional IFNGR may activate Stat1 more slowly, thereby producing lower levels of IRF-1 that are not sufficient to induce apoptosis [35 ]. Experiments in which overexpression of functional IFNGR on normally low-level IFNGR-expressing cells changed the IFN-{gamma} response of these cells from an antiapoptotic/proliferative phenotype to a proapoptotic phenotype are consistent with this hypothesis [35 ]. This may also explain why myeloid cells are more sensitive to the proapoptotic actions of IFN-{gamma} than other cells such as T cells, as myeloid cells express relatively high numbers of functional IFNGR on the cell surface [35 ].

Many of the proapoptotic effects of IRF-1 are mediated by the IRF-1-induced caspase 1 (IL-1ß-converting enzyme) [267 268 269 ]. Caspase 1 is a cysteine protease implicated in mediating macrophage apoptosis by various stimuli including LPS [351 352 353 ] and is involved in generation of bioactive IL-1ß and IL-18 [354 ]. Caspase 1 expression and resulting apoptosis can be IFN-{gamma}-inducible [269 ] or can occur through IFN-{gamma}-independent IRF-1 activity [267 ]. IFN-{gamma} also induces a number of other proapoptotic molecules. These include PKR, the DAPs, cathepsin D, and surface expression of Fas and the TNF-{alpha} receptor (Table 1) .

Activation of microbicidal effector functions
One of the most important effects of IFN-{gamma} on macrophages is the activation of microbicidal effector functions. Macrophages activated by IFN-{gamma} display increased pinocytosis and receptor-mediated phagocytosis as well as enhanced microbial killing ability. IFN-{gamma}-activated microbicidal ability includes induction of the NADPH-dependent phagocyte oxidase (NADPH oxidase) system ("respiratory burst"), priming for NO production, tryptophan depletion, and up-regulation of lysosomal enzymes promoting microbe destruction (Table 1) [222 ]. Similar microbicidal mechanisms are activated by IFN-{gamma} in neutrophils [4 ].

Macrophages kill bacteria, viruses, protozoa, helminths, fungi, and tumor cells primarily by production of ROS and reactive nitrogen intermediates (RNI) via induction of the NADPH oxidase system and iNOS, respectively (reviewed in refs. [281 , 355 , 356 ]). ROS and RNI use the advantages of low molecular weight, reactivity, and lipophilicity to easily penetrate the microbial cell wall/coat to inflict injury. The importance of these molecules in host defense is highlighted by the highly pathogen-susceptible phenotype of mice doubly deficient in NADPH oxidase and iNOS enzymes [357 ]. The timeframes and situations in which macrophage use these cytocidal activities are generally different. ROS production becomes apparent within 1 h after stimulus, whereas RNI generation requires ~24 h after encountering a pathogen product. In general, ROS are used to target extracellular pathogens during phagocytosis or that are too large for phagocytosis, whereas RNI target intracellular pathogens and upon appropriate stimulus, extracellular pathogens and tumor cells.

NO is produced in the NADPH-dependent conversion of L-arginine to L-citrulline by the NOS enzymes (NOS1–3). The NOS2/iNOS isoform alone is inducible by cytokine and/or microbial stimulus [281 ]. The NO generated by this enzyme exists in equilibrium among a number of different redox states (called RNI in this review) that have differing biological activities. It should be noted that much of the work presented below applies to mice rather than humans, and there is at present much controversy of the physiological relevance of NO production in human host defense (reviewed in ref. [281 ]).

A wealth of evidence supports a crucial function of iNOS and RNI in host defense (reviewed in ref. [281 ]). IFN-{gamma}-dependent RNI production is associated with increased ability of phagocytic cells to kill ingested pathogens, and this ability is inhibited by the addition of a substrate analog inhibitor of iNOS such as N-methyl-L-arginine [358 359 360 361 ]. Furthermore, mice in which the iNOS gene has been mutated show greater susceptibility to parasitic infection and a dampened, nonspecific inflammatory response [362 ]. Production of RNI also inhibits replication of a range of viruses, through ill-defined mechanisms [358 , 363 , 364 ].

IFN-{gamma} induces RNI production by up-regulating expression of substrate, cofactor, and catalyst required for NO generation. IFN-{gamma} up-regulates argininosuccinate synthetase (which produces the L-arginine substrate), GTP-cyclohydroxylase I (which supplies the tetrahydrobiopterin cofactor required for NO production), and the iNOS enzyme [285 , 286 , 365 366 367 ]. Maximal induction of iNOS transcription requires "priming" and "triggering" stimuli such as priming with IFN-{gamma} and subsequent triggering with LPS or TNF-{alpha} [368 , 369 ]. The type I IFNs cannot fully substitute for IFN-{gamma} in triggering NO production [368 ].

Superoxide and its reactive products are also important toxic effector molecules of the nonspecific cytotoxic response. The superoxide anion, O2-, is generated by the multicomponent flavocytochrome enzyme phagocyte oxidase during a process called respiratory burst. This enzyme is composed of two cytochrome b558 subunits, gp91phox and gp22phox, concentrated in the phagosome membrane, and two cytosolic components, p47phox and p67phox. Upon appropriate stimulus (e.g., phagocytosis), the cytosolic components translocate to the membrane to form the active complex, which generates superoxide in the phagosome through transfer of a transported electron to molecular oxygen. The superoxide anion generated by the respiratory burst spontaneously reacts to form hydrogen peroxide (H2O2), hydroxyl radicals (·OH), and hypochlorous acid (HOCl) [281 ]. The toxic oxidants produced by the respiratory burst are also able to react with those produced by iNOS, thereby forming a large number of different toxic species (e.g., peroxynitrite) to mediate cytotoxicity by a wide variety of mechanisms [281 , 370 , 371 ].

The primary mechanism of IFN-{gamma}-induced up-regulation of ROS production in phagocytes is transcriptional induction of the gp91phox and p67phox subunits of the NADPH oxidase complex [287 288 289 , 372 ]. The biological importance of this pathway in host defense is emphasized by the human genetic disease, chronic granulomatous disease, caused by defects in the NADPH oxidase system and characterized by recurrent and often fatal infections.

IFN-{gamma} also promotes microbe destruction by augmenting surface expression of the high-affinity Fc{gamma}RI on mononuclear phagocytes, thereby promoting antibody-dependent, cell-mediated cytotoxicity [291 ]. Complement-mediated phagocytosis is also up-regulated by IFN-{gamma} through increased complement secretion and complement receptor surface expression on mononuclear phagocytes [292 ].

Tryptophan depletion from cells in response to IFN-{gamma} may be an antiparasitic mechanism in humans [373 ]. IFN-{gamma} up-regulates the expression of indoeamine 2,3 dioxygenase, an enzyme responsible for the generation of N-formylkynurenine from tryptophan [374 375 376 377 ]. It is interesting that IFN-{gamma} also induces expression of tryptophanyl-tRNA synthetase, a housekeeping gene that catalyzes tRNA Trp aminoacetylation during protein synthesis [378 , 379 ]. It is proposed that this enzyme may also aid in tryptophan depletion by incorporating free tryptophan into translating protein and may ensure synthesis of Trp-rich proteins with immunologically important functions (e.g., the IRF family and many MHC molecules) during cellular tryptophan depletion [380 ].

Immunomodulation and leukocyte trafficking
The ability of IFN-{gamma} to coordinate the transition from innate immunity to adaptive immunity distinguishes it from the other IFNs. Mechanisms by which IFN-{gamma} coordinates this transition include aiding in the development of a Th1-type response (described earlier), directly promoting B cell isotype switching to IgG2a [54 , 381 , 382 ], and regulation of local leukocyte-endothelial interactions (Table 1) .

IFN-{gamma} orchestrates the trafficking of specific immune cells to sites of inflammation through up-regulating expression of adhesion molecules and chemokines. Unstimulated leukocytes cycle continuously between the blood and the lymph. IFN-{gamma} and NO produced at the site of inflammation cause local dilation of the blood vessels, thereby decreasing the local blood flow rate and causing gathering of blood in leaky vessels. Specific leukocyte subsets are instructed by the cytokine/chemokine milieu to extravasate into the tissue via interactions between adhesion molecules presented on leukocyte and endothelial surfaces ("diapedesis") [4 ]. IFN-{gamma} regulates this process by up-regulating expression of chemokines (e.g., IP-10, MCP-1, MIG, MIP-1{alpha}/ß, RANTES; see Table 1 ) and adhesion molecules (e.g., ICAM-1, VCAM-1; see Table 1 ). TNF-{alpha} and IL-1ß synergistically regulate many of these molecules [4 ].

IFN-{gamma} priming of the macrophage LPS response
LPS/endotoxin is a cell wall constituent of gram-negative bacteria that activates macrophage microbicidal effector functions and the production of proinflammatory cytokines (e.g., TNF-{alpha}, IL-1, IL-6). LPS:macrophage interaction can be beneficial or deleterious to the host. Macrophages sense and are activated to fight and clear bacterial infection through LPS recognition, a mechanism obviously advantageous to the host; however, high doses of LPS that trigger excessive production of inflammatory mediators can result in the potentially lethal systemic disorder, septic shock.

Macrophages recognition of lipid A (the active moiety of LPS), requires Toll-like receptor (TLR) family member TLR4. The TLR family is a homolog of the Drosophila antifungal protein Toll. To date, 10 mammalian TLRs have been identified (TLR1–10), and many have proposed or demonstrated functions in innate immunity. LPS:TLR4 interaction triggers a signaling cascade (Fig. 3 ), which ultimately results in activation of NF-{kappa}B and activated protein-1 (AP-1) and transcriptional control over genes directing immune function in macrophages (reviewed in refs. [383 384 385 386 ]). MyD88 functions as an adaptor to connect the intracellular portion of TLR4 to downstream signaling components and is required for many, but not all, LPS-induced effects [387 ]. For this reason, a TLR4 signaling paradigm has emerged in which LPS signals through MyD88-dependent and MyD88-independent pathways. MyD88 gene KO mice demonstrated that the MyD88-dependent pathway is necessary for rapid activation of MAPK, AP-1, and NF-{kappa}B, the production of inflammatory cytokines, and septic shock [387 ]. The MyD88-independent pathway results in slower activation of MAPK, AP-1, and NF-{kappa}B and does not contribute to the same extent to the inflammatory response.



View larger version (15K):
[in this window]
[in a new window]
  		Figure 3. The current paradigm for optimal LPS signal transduction through TLR4. The LPS:LPS-binding protein (LBP) complex binds to CD14. The LPS:LBP:CD14 complex probably activates TLR4, and optimal LPS-induced signaling requires the association of the MD-2 accessory component with the TLR4 extracellular domain. Downstream signaling is dependent on sequential recruitment and activation of signaling molecules. In the MyD88-dependent pathway, the signaling adaptor MyD88 is recruited to the receptor, and the signal is relayed via sequential recruitment and activation of the serine/threonine kinase IL-1R-associated kinase (IRAK), TNF receptor-associated factor (TRAF)6, NF-{kappa}B-inducing kinase (NIK), and I{kappa}B kinase for the rapid activation of NF-{kappa}B and AP-1 (IKK). MyD88 adaptor-like/Toll/IL-1 receptor/resistance (TIR) domain-containing adaptor protein also contributes to the MyD88-dependent pathway, through ill-defined mechanisms. The MyD88-independent pathway is less well characterized but involves activation of IRF-3 and more slowly activates NF-{kappa}B and AP-1. It has recently been suggested that TIR domain-containing adaptor-inducing IFN-ß (TRIF) participates in the MyD88-independent pathway upstream of IRF-3. Activation of the MyD88-dependent and -independent pathways also activates the mitogen-activated protein kinase (MAPK) pathways, c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), p38 MAPK, and extracellular-regulated kinase (ERK) pathways. The MyD88-dependent pathway ultimately controls transcription of target genes, including many of the proinflammatory cytokines implicated in the pathophysiology of septic shock. Genes regulated by the MyD88-independent pathway, however, do not contribute to septic shock to the same extent. Possible mechanisms giving rise to the priming effect apparent when LPS-stimulated macrophages are pretreated with IFN-{gamma} include (numbered on the figure): (1) IFN-{gamma} up-regulates expression of the TLR4 and MD-2 components of the LPS recognition complex; (2) IFN-{gamma} upregulates expression of MyD88 and IRAK; (3) LPS activates Stat1, possibly through the MAPK pathway, thus augmenting the IFN-{gamma} response; (4) IFN-{gamma} promotes LPS-induced NF-{kappa}B activation; (5) LPS induces type I IFN, which may participate in cross-talk with the IFN-{gamma} signaling pathway to augment the macrophage IFN-{gamma} response; and (6) LPS/TNF-{alpha}- and IFN-{gamma}-activated/induced signaling molecules can often bind to promoter regions of target genes to synergistically regulate transcription. GARG, Glucocorticoid attenuated response gene; IRG, immune-responsive gene.

IFN-{gamma} primes macrophages for more rapid and heightened responses to LPS [58 , 388 , 389 ] as well as other TLR agonists, such as unmethylated CpG motifs present in bacterial DNA (CpG DNA) [390 ]. Pretreatment with IFN-{gamma} is necessary for the induction of some genes in response to LPS. iNOS is the archetypal example of such a gene, although the need for exogenous priming by IFN-{gamma} can be overcome by adequate production of endogenous type I IFN in response to high doses of LPS [391 ]. For other genes, IFN-{gamma} is able to shift the dose-response curve such that transcription is induced at lower concentrations of LPS, thereby superinducing transcription in IFN-{gamma}-primed cells treated with LPS compared with the same concentration of LPS alone [392 ]. IFN-{gamma} priming does not occur for all LPS-induced responses; IFN-{gamma} appears to prime for a select subset of LPS-induced genes. For example, IFN-{gamma} pretreatment promotes LPS-induced TNF-{alpha} but not procoagulant activity enzyme production [393 ].

IFN-{gamma} receptor KO mice are highly resistant to LPS-induced toxicity [394 ]. This highlights the physiological significance of IFN-{gamma} priming in vivo, as it demonstrates that IFN-{gamma} is normally produced during the response to LPS and acts to amplify LPS-induced cellular responses. The priming phenomenon relies on IFN-{gamma} and LPS reciprocal cross-regulation of signaling molecules of the other pathway.

IFN-{gamma} influences LPS-dependent signaling capabilities by promoting ligand-receptor interactions as well as downstream signaling machinery. Efficient LPS:TLR4 interaction requires the MD-2 and CD14 accessory molecules, and subsequent maximal signaling requires MyD88 signaling adaptor. In a number of experiments, IFN-{gamma} was shown to promote transcription of TLR4, subsequent TLR4 surface expression, and LPS-binding ability in macrophages [395 396 397 ]. Furthermore, IFN-{gamma} inhibits the LPS-dependent down-regulation of TLR4 surface expression apparent in unprimed cells [395 ]. IFN-{gamma} stimulation may also promote LPS-dependent signaling by promoting expression of the MD-2 accessory molecule, the MyD88 adaptor, and the IRAK signaling molecule [395 , 398 ].

LPS mediates many of its effects through the NF-{kappa}B transcription factor. In the macrophage-like cell line RAW264.7, it was found that IFN-{gamma} pretreatment promoted NF-{kappa}B activation upon LPS exposure, as well as more rapid DNA-binding kinetics and faster degradation of the NF-{kappa}B inhibitor, I{kappa}B-{alpha} [399 ]. In human monocytes also, IFN-{gamma} pretreatment causes superinduction of active NF-{kappa}B upon LPS treatment [400 ]. When these cells were unstimulated, they exhibited high levels of the p50 subunit of NF-{kappa}B but only low levels of p65. IFN-{gamma} priming caused an increase in p65 mRNA as a result of increased transcript stability.

Many IFN-{gamma}-inducible genes are also TNF-{alpha}-inducible, and these genes are often superinduced by the combination of these factors [366 , 372 , 401 , 402 ]. TNF-{alpha} is a macrophage-derived cytokine secreted in response to LPS, which can act in an autocrine manner to mediate many LPS-induced effects via NF-{kappa}B [403 ]. IFN-{gamma} priming of TNF-{alpha} responses is thus responsible for the priming of a subset of LPS-induced genes. In many cases, synergistic induction by the combination of these factors may be a result of the combined presence of Stat1 and NF-{kappa}B-binding sites in the promoter elements of responsive genes [160 , 404 ]. Synergy may be also be a result of cross-talk between the IFN-{gamma} and TNF-{alpha} signaling pathways: TNF-{alpha} stimulation is able to induce transcription of IRF-1 and promotes IFN-{gamma}-induced Stat1 activation [405 , 406 ]; IFN-{gamma}-induced PKR is able to signal to NF-{kappa}B [407 ]; and IFN-{gamma} increases surface expression of the TNF-{alpha} receptor [280 , 408 , 409 ], although the significance of this is uncertain, as an increased receptor expression level has not been linked with increased response to TNF-{alpha} [410 , 411 ].

Although probably not complete, these mechanisms of increasing cellular sensitivity to LPS may start to explain the shift in the LPS dose-response curve seen with IFN-{gamma} priming. Genes that need IFN-{gamma} and LPS treatment for induction may require a certain threshold of LPS signaling for transactivation, and so IFN-{gamma} treatment shifts the LPS dose-response curve by increasing cellular sensitivity. Alternatively, these genes may require specific cross-talk between pathways before transcriptional activation can occur. Examples of such cross-talk may include LPS-induced Stat1 serine phosphorylation or cross-talk between IFN-{gamma}- and LPS-induced type I IFN pathways.

LPS is able to promote the IFN-{gamma} signaling pathway through Stat1. As noted earlier, phosphorylation of S727 of Stat1 occurs in response to IFN-{gamma} or LPS exposure and is necessary for maximal Stat1 activation. LPS treatment following IFN-{gamma} exposure increases the percentage of molecules phosphorylated on Y701 and S727 and subsequent Stat1 DNA-binding activity relative to IFN-{gamma} treatment alone, thereby augmenting IFN-{gamma}-dependent, Stat1-mediated gene expression [123 , 223 ]. IFN-{gamma} and LPS may use different pathways for Stat1 serine phosphorylation, as LPS-induced Stat1 serine phosphorylation is sensitive to a p38 MAPK inhibitor, whereas the serine phosphorylation induced by IFN-{gamma} is not [110 ]. Another study suggested that although p38 MAPK is necessary, it is not sufficient for Stat1 serine phosphorylation by LPS, and protein kinase C-{delta} is also required to mediate phosphorylation [412 ]. In addition to promoting serine phosphorylation, LPS treatment following IFN-{gamma} exposure augments Stat1 tyrosine phosphorylation of residue 701 [399 ]. Macrophage exposure to LPS triggers production of endogenous type I IFN that can act on the macrophage population in an autocrine/paracrine manner. This has been identified as the causal agent of LPS-induced Stat1 tyrosine phosphorylation [413 ].

It has long been recognized that LPS induces transcription of type I IFN [414 ], but only in recent years has the significance of autocrine/paracrine functions of type I IFN in mediating LPS-induced gene expression been acknowledged [391 , 415 , 416 ]. Stat1 is tyrosine-phosphorylated as a result of autocrine/paracrine type I IFN and is required for the full LPS response in IFN-{gamma}-unprimed macrophages [416 ]. LPS-induced Stat1 Y701 phosphorylation was found to be essential for iNOS expression [413 ], and macrophages from mice unable to respond to type I IFN through targeted disruption of the IFNAR1 receptor subunit exhibited limited capacity to induce iNOS in response to LPS [391 ]. iNOS-producing capacity in response to LPS was able to be rescued by exposure to IFN-{gamma}, which presumably restored Stat1 activation [391 ]. LPS induces transcription of type I IFN through an ill-defined, MyD88-independent pathway involving IRF-3 [417 ]. The contribution of type I IFN to IFN-{gamma} priming of the LPS response has not been formally studied; however, as IFN-{gamma} up-regulates expression of IFNAR in other cell types (P. J. Hertzog, unpublished observations) and promotes IFN-{alpha}/ß expression, it is possible that IFN-{gamma} sensitizes the cells to LPS-induced IFN-{alpha}/ß. When the many levels of cross-talk between the IFN-{gamma} and IFN-{alpha}/ß pathway are considered, it is likely that in vivo IFN-{gamma} potentiates LPS-induced IFN-{alpha}/ß effects and conversely, LPS augments IFN-{gamma}-mediated effects (e.g., by Stat1 Y701 and S727 phosphorylation).

Synergy between LPS- and IFN-{gamma}-induced transcription factors in expression of target genes also contributes to the priming phenotype. Genes such as IRF-1, IP-10, ICAM-1, and iNOS contain Stat1 and NF-{kappa}B-binding sites in their promoter, and maximal transcription requires both signals [158 , 160 , 402 , 404 , 418 419 420 421 422 423 ]. This is a demonstrated mechanism in IFN-{gamma}-dependent gene superinduction in response to LPS for a number of genes and is likely to be a global mechanism for synergistic, coordinate regulation of large synexpression groups. Genes that require IFN-{gamma} and LPS treatment for induction (e.g., iNOS) may also be explained by this mechanism, as it is likely that the IFN-{gamma}- and LPS-induced transcription factors are limiting for gene induction at a single-cell level. This theory is consistent with the all-or-nothing transcription of iNOS and many other IFN-{gamma}/LPS-regulated genes observed at a single-cell level (ref. [424 ] and references therein).


arrow
CONCLUDING REMARKS
 
IFN-{gamma} is a remarkable cytokine that orchestrates many distinct cellular programs through transcriptional control over large numbers of genes. Many IFN-{gamma}-induced effects resulting in heightened immune surveillance and immune system function during infection have been discussed in this review. As pathogen products such as LPS and CpG DNA augment local IFN-{gamma} production, and IFN-{gamma} augments the immune system response to these agonists, an important function of IFN-{gamma} during in vivo infection is suggested, whereby IFN-{gamma} participates in an amplification loop to increase immune system sensitivity and response to pathogens. This model is supported by the in vivo and in vitro priming phenotype apparent when LPS-stimulated macrophages are pretreated with IFN-{gamma}, and also by the high resistance of IFNGR-/- mice to LPS-induced septic shock.

The ability of IFN-{gamma} to synergize or antagonize the effects of cytokines, growth factors, and pathogen-associated molecular pattern (PAMP)-signaling pathways (e.g., TNF-{alpha}, IL-4, CSF-1, IFN-{alpha}/ß, LPS, and CpG DNA) is particularly important in macrophage biology, as macrophages constantly receive multiple signals and need to integrate them to give a response appropriate to the extracellular milieu. The reductionist approach used by many scientists has greatly furthered our understanding of mechanisms by which IFN-{gamma} coordinates its pleiotropic effects. However, a cell is not exposed to one stimulus in isolation in vivo, and so, one of the great challenges to IFN biologists today is to understand the mechanisms by which IFN-{gamma} signaling and cellular effects integrate with other growth factor, cytokine, and PAMP signaling pathways. This understanding will enable a more realistic view of in vivo macrophage function during naturally occurring human infection.


arrow
ACKNOWLEDGEMENTS
 
The authors thank Katharine Irvine for critical reading of the manuscript and helpful suggestions.

Received June 2, 2003; revised July 25, 2003; accepted July 27, 2003.


arrow
REFERENCES
 
    1
  1. Adams, D. O. (1989) Molecular interactions in macrophage activation Immunol. Today 10,33-35[CrossRef][Medline]
    2. 2
  2. Perussia, B., Dayton, E. T., Fanning, V., Thiagarajan, P., Hoxie, J., Trinchieri, G. (1983) Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway J. Exp. Med. 158,2058-2080[Abstract/Free Full Text]
    3. 3
  3. Young, H. A., Hardy, K. J. (1995) Role of interferon-gamma in immune cell regulation J. Leukoc. Biol. 58,373-381[Abstract]
    4. 4
  4. Boehm, U., Klamp, T., Groot, M., Howard, J. C. (1997) Cellular responses to interferon-gamma Annu. Rev. Immunol. 15,749-795[CrossRef][Medline]
    5. 5
  5. Carnaud, C., Lee, D., Donnars, O., Park, S. H., Beavis, A., Koezuka, Y., Bendelac, A. (1999) Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells J. Immunol. 163,4647-4650[Abstract/Free Full Text]
    6. 6
  6. Finkelman, F. D., Katona, I. M., Mosmann, T. R., Coffman, R. L. (1988) IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses J. Immunol. 140,1022-1027[Abstract]
    7. 7
  7. Isaacs, A., Lindermann, J. (1957) Virus interference. I. The interferon Proc. R. Soc. Lond. B Biol. Sci. 147,258-267[Medline]
    8. 8
  8. Bach, E. A., Aguet, M., Schreiber, R. D. (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling Annu. Rev. Immunol. 15,563-591[CrossRef][Medline]
    9. 9
  9. Jonasch, E., Haluska, F. G. (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities Oncologist 6,34-55[Abstract/Free Full Text]
    10. 10
  10. Bazer, F. W., Spencer, T. E., Ott, T. L. (1997) Interferon tau: a novel pregnancy recognition signal Am. J. Reprod. Immunol. 37,412-420
    11. 11
  11. Young, H. A. (1996) Regulation of interferon-gamma gene expression J. Interferon Cytokine Res. 16,563-568[Medline]
    12. 12
  12. Frucht, D. M., Fukao, T., Bogdan, C., Schindler, H., O’Shea, J. J., Koyasu, S. (2001) IFN-gamma production by antigen-presenting cells: mechanisms emerge Trends Immunol. 22,556-560[CrossRef][Medline]
    13. 13
  13. Gessani, S., Belardelli, F. (1998) IFN-gamma expression in macrophages and its possible biological significance Cytokine Growth Factor Rev. 9,117-123[CrossRef][Medline]
    14. 14
  14. Yoshimoto, T., Takeda, K., Tanaka, T., Ohkusu, K., Kashiwamura, S., Okamura, H., Akira, S., Nakanishi, K. (1998) IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production J. Immunol. 161,3400-3407[Abstract/Free Full Text]
    15. 15
  15. Flaishon, L., Hershkoviz, R., Lantner, F., Lider, O., Alon, R., Levo, Y., Flavell, R. A., Shachar, I. (2000) Autocrine secretion of interferon gamma negatively regulates homing of immature B cells J. Exp. Med. 192,1381-1388[Abstract/Free Full Text]
    16. 16
  16. Harris, D. P., Haynes, L., Sayles, P. C., Duso, D. K., Eaton, S. M., Lepak, N. M., Johnson, L. L., Swain, S. L., Lund, F. E. (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells Nat. Immunol. 1,475-482[CrossRef][Medline]
    17. 17
  17. Sen, G. C. (2001) Viruses and interferons Annu. Rev. Microbiol. 55,255-281[CrossRef][Medline]
    18. 18
  18. Golab, J., Zagozdzon Stoklosal, T., Kaminski, R., Kozar, K., Jakobisiak, M. (2000) Direct stimulation of macrophages by IL-12 and IL-18–a bridge too far? Immunol. Lett. 72,153-157[CrossRef][Medline]
    19. 19
  19. Munder, M., Mallo, M., Eichmann, K., Modolell, M. (2001) Direct stimulation of macrophages by IL-12 and IL-18—a bridge built on solid ground Immunol. Lett. 75,159-160[CrossRef][Medline]
    20. 20
  20. Munder, M., Mallo, M., Eichmann, K., Modolell, M. (1998) Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation J. Exp. Med. 187,2103-2108[Abstract/Free Full Text]
    21. 21
  21. Fukao, T., Matsuda, S., Koyasu, S. (2000) Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells J. Immunol. 164,64-71[Abstract/Free Full Text]
    22. 22
  22. Otani, T., Nakamura, S., Toki, M., Motoda, R., Kurimoto, M., Orita, K. (1999) Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice Cell. Immunol. 198,111-119[CrossRef][Medline]
    23. 23
  23. Akira, S. (2000) The role of IL-18 in innate immunity Curr. Opin. Immunol. 12,59-63[CrossRef][Medline]
    24. 24
  24. Dinarello, C. A. (1999) IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family J. Allergy Clin. Immunol. 103,11-24[CrossRef][Medline]
    25. 25
  25. Salazar-Mather, T. P., Hamilton, T. A., Biron, C. A. (2000) A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense J. Clin. Invest. 105,985-993[Medline]
    26. 26
  26. Pien, G. C., Satoskar, A. R., Takeda, K., Akira, S., Biron, C. A. (2000) Cutting edge: selective IL-18 requirements for induction of compartmental IFN-gamma responses during viral infection J. Immunol. 165,4787-4791[Abstract/Free Full Text]
    27. 27
  27. Schindler, H., Lutz, M. B., Rollinghoff, M., Bogdan, C. (2001) The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4 J. Immunol. 166,3075-3082[Abstract/Free Full Text]
    28. 28
  28. Fukao, T., Frucht, D. M., Yap, G., Gadina, M., O’Shea, J. J., Koyasu, S. (2001) Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses J. Immunol. 166,4446-4455[Abstract/Free Full Text]
    29. 29
  29. Hochrein, H., Shortman, K., Vremec, D., Scott, B., Hertzog, P., O’Keeffe, M. (2001) Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets J. Immunol. 166,5448-5455[Abstract/Free Full Text]
    30. 30
  30. Major, A. S., Cuff, C. F. (1996) Effects of the route of infection on immunoglobulin G subclasses and specificity of the reovirus-specific humoral immune response J. Virol. 70,5968-5974[Abstract]
    31. 31
  31. Autenrieth, I. B., Reissbrodt, R., Saken, E., Berner, R., Vogel, U., Rabsch, W., Heesemann, J. (1994) Desferrioxamine-promoted virulence of Yersinia enterocolitica in mice depends on both desferrioxamine type and mouse strain J. Infect. Dis. 169,562-567[Medline]
    32. 32
  32. Autenrieth, I. B., Beer, M., Bohn, E., Kaufmann, S. H., Heesemann, J. (1994) Immune responses to Yersinia enterocolitica in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon Infect. Immun. 62,2590-2599[Abstract/Free Full Text]
    33. 33
  33. Bazan, J. F. (1990) Structural design and molecular evolution of a cytokine receptor superfamily Proc. Natl. Acad. Sci. USA 87,6934-6938[Abstract/Free Full Text]
    34. 34
  34. Thoreau, E., Petridou, B., Kelly, P. A., Djiane, J., Mornon, J. P. (1991) Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis FEBS Lett. 282,26-31[CrossRef][Medline]
    35. 35
  35. Bernabei, P., Coccia, E. M., Rigamonti, L., Bosticardo, M., Forni, G., Pestka, S., Krause, C. D., Battistini, A., Novelli, F. (2001) Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death J. Leukoc. Biol. 70,950-960[Abstract/Free Full Text]
    36. 36
  36. Pernis, A., Gupta, S., Gollob, K. J., Garfein, E., Coffman, R. L., Schindler, C., Rothman, P. (1995) Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in TH1 cells Science 269,245-247[Abstract/Free Full Text]
    37. 37
  37. Bach, E. A., Szabo, S. J., Dighe, A. S., Ashkenazi, A., Aguet, M., Murphy, K. M., Schreiber, R. D. (1995) Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets Science 270,1215-1218[Abstract/Free Full Text]
    38. 38
  38. Maggi, E., Parronchi, P., Manetti, R., Simonelli, C., Piccinni, M. P., Rugiu, F. S., De Carli, M., Ricci, M., Romagnani, S. (1992) Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones J. Immunol. 148,2142-2147[Abstract]
    39. 39
  39. Gajewski, T. F., Fitch, F. W. (1988) Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones J. Immunol. 140,4245-4252[Abstract]
    40. 40
  40. Kaplan, D. H., Greenlund, A. C., Tanner, J. W., Shaw, A. S., Schreiber, R. D. (1996) Identification of an interferon-gamma receptor alpha chain sequence required for JAK-1 binding J. Biol. Chem. 271,9-12[Abstract/Free Full Text]
    41. 41
  41. Greenlund, A. C., Farrar, M. A., Viviano, B. L., Schreiber, R. D. (1994) Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91) EMBO J. 13,1591-1600[Medline]
    42. 42
  42. Farrar, M. A., Fernandez-Luna, J., Schreiber, R. D. (1991) Identification of two regions within the cytoplasmic domain of the human interferon-gamma receptor required for function J. Biol. Chem. 266,19626-19635[Abstract/Free Full Text]
    43. 43
  43. Farrar, M. A., Campbell, J. D., Schreiber, R. D. (1992) Identification of a functionally important sequence in the C terminus of the interferon-gamma receptor Proc. Natl. Acad. Sci. USA 89,11706-11710[Abstract/Free Full Text]
    44. 44
  44. Cook, J. R., Jung, V., Schwartz, B., Wang, P., Pestka, S. (1992) Structural analysis of the human interferon gamma receptor: a small segment of the intracellular domain is specifically required for class I major histocompatibility complex antigen induction and antiviral activity Proc. Natl. Acad. Sci. USA 89,11317-11321[Abstract/Free Full Text]
    45. 45
  45. Farrar, M. A., Schreiber, R. D. (1993) The molecular cell biology of interferon-gamma and its receptor Annu. Rev. Immunol. 11,571-611[CrossRef][Medline]
    46. 46
  46. Kotenko, S. V., Izotova, L. S., Pollack, B. P., Mariano, T. M., Donnelly, R. J., Muthukumaran, G., Cook, J. R., Garotta, G., Silvennoinen, O., Ihle, J. N., et al (1995) Interaction between the components of the interferon gamma receptor complex J. Biol. Chem. 270,20915-20921[Abstract/Free Full Text]
    47. 47
  47. Bach, E. A., Tanner, J. W., Marsters, S., Ashkenazi, A., Aguet, M., Shaw, A. S., Schreiber, R. D. (1996) Ligand-induced assembly and activation of the gamma interferon receptor in intact cells Mol. Cell. Biol. 16,3214-3221[Abstract]
    48. 48
  48. Pestka, S., Kotenko, S. V., Muthukumaran, G., Izotova, L. S., Cook, J. R., Garotta, G. (1997) The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor Cytokine Growth Factor Rev. 8,189-206[CrossRef][Medline]
    49. 49
  49. Muthukumaran, G., Donnelly, R. J., Ebensperger, C., Mariano, T. M., Garotta, G., Dembic, Z., Poast, J., Baron, S., Pestka, S. (1996) The intracellular domain of the second chain of the interferon-gamma receptor is interchangeable between species J. Interferon Cytokine Res. 16,1039-1045[Medline]
    50. 50
  50. Gibbs, V. C., Williams, S. R., Gray, P. W., Schreiber, R. D., Pennica, D., Rice, G., Goeddel, D. V. (1991) The extracellular domain of the human interferon gamma receptor interacts with a species-specific signal transducer Mol. Cell. Biol. 11,5860-5866[Abstract/Free Full Text]
    51. 51
  51. Hibino, Y., Kumar, C. S., Mariano, T. M., Lai, D. H., Pestka, S. (1992) Chimeric interferon-gamma receptors demonstrate that an accessory factor required for activity interacts with the extracellular domain J. Biol. Chem. 267,3741-3749[Abstract/Free Full Text]
    52. 52
  52. Hemmi, S., Merlin, G., Aguet, M. (1992) Functional characterization of a hybrid human-mouse interferon gamma receptor: evidence for species-specific interaction of the extracellular receptor domain with a putative signal transducer Proc. Natl. Acad. Sci. USA 89,2737-2741[Abstract/Free Full Text]
    53. 53
  53. Kalina, U., Ozmen, L., Di Padova, K., Gentz, R., Garotta, G. (1993) The human gamma interferon receptor accessory factor encoded by chromosome 21 transduces the signal for the induction of 2',5'-oligoadenylate-synthetase, resistance to virus cytopathic effect, and major histocompatibility complex class I antigens J. Virol. 67,1702-1706[Abstract/Free Full Text]
    54. 54
  54. Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R., Vilcek, J., Zinkernagel, R. M., Aguet, M. (1993) Immune response in mice that lack the interferon-gamma receptor Science 259,1742-1745[Abstract/Free Full Text]
    55. 55
  55. Pearl, J. E., Saunders, B., Ehlers, S., Orme, I. M., Cooper, A. M. (2001) Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse Cell. Immunol. 211,43-50[CrossRef][Medline]
    56. 56
  56. van den Broek, M. F., Muller, U., Huang, S., Zinkernagel, R. M., Aguet, M. (1995) Immune defence in mice lacking type I and/or type II interferon receptors Immunol. Rev. 148,5-18[CrossRef][Medline]
    57. 57
  57. Buchmeier, N. A., Schreiber, R. D. (1985) Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection Proc. Natl. Acad. Sci. USA 82,7404-7408[Abstract/Free Full Text]
    58. 58
  58. Kamijo, R., Le, J., Shapiro, D., Havell, E. A., Huang, S., Aguet, M., Bosland, M., Vilcek, J. (1993) Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide J. Exp. Med. 178,1435-1440[Abstract/Free Full Text]
    59. 59
  59. Suzuki, Y., Orellana, M. A., Schreiber, R. D., Remington, J. S. (1988) Interferon-gamma: the major mediator of resistance against Toxoplasma gondii Science 240,516-518[Abstract/Free Full Text]
    60. 60
  60. Muller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., Aguet, M. (1994) Functional role of type I and type II interferons in antiviral defense Science 264,1918-1921[Abstract/Free Full Text]
    61. 61
  61. Kimura, T., Kadokawa, Y., Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Tarutani, M., Tan, R. S., Takasugi, T., Matsuyama, T., Mak, T. W., Noguchi, S., Taniguchi, T. (1996) Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies Genes Cells 1,115-124[Abstract]
    62. 62
  62. Biron, C. A. (2001) Interferons alpha and beta as immune regulators–a new look Immunity 14,661-664[CrossRef][Medline]
    63. 63
  63. Doffinger, R., Jouanguy, E., Dupuis, S., Fondaneche, M. C., Stephan, J. L., Emile, J. F., Lamhamedi-Cherradi, S., Altare, F., Pallier, A., Barcenas-Morales, G., Meinl, E., Krause, C., Pestka, S., Schreiber, R. D., Novelli, F., Casanova, J. L. (2000) Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection J. Infect. Dis. 181,379-384[CrossRef][Medline]
    64. 64
  64. Jouanguy, E., Lamhamedi-Cherradi, S., Lammas, D., Dorman, S. E., Fondaneche, M. C., Dupuis, S., Doffinger, R., Altare, F., Girdlestone, J., Emile, J. F., Ducoulombier, H., Edgar, D., Clarke, J., Oxelius, V. A., Brai, M., Novelli, V., Heyne, K., Fischer, A., Holland, S. M., Kumararatne, D. S., Schreiber, R. D., Casanova, J. L. (1999) A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection Nat. Genet. 21,370-378[CrossRef][Medline]
    65. 65
  65. Jouanguy, E., Lamhamedi-Cherradi, S., Altare, F., Fondaneche, M. C., Tuerlinckx, D., Blanche, S., Emile, J. F., Gaillard, J. L., Schreiber, R., Levin, M., Fischer, A., Hivroz, C., Casanova, J. L. (1997) Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis J. Clin. Invest. 100,2658-2664[Medline]
    66. 66
  66. Jouanguy, E., Altare, F., Lamhamedi-Cherradi, S., Casanova, J. L. (1997) Infections in IFNGR-1-deficient children J. Interferon Cytokine Res. 17,583-587[Medline]
    67. 67
  67. Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., Levin, M. (1996) A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection N. Engl. J. Med. 335,1941-1949[Abstract/Free Full Text]
    68. 68
  68. Pierre-Audigier, C., Jouanguy, E., Lamhamedi, S., Altare, F., Rauzier, J., Vincent, V., Canioni, D., Emile, J. F., Fischer, A., Blanche, S., Gaillard, J. L., Casanova, J. L. (1997) Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency Clin. Infect. Dis. 24,982-984[Medline]
    69. 69
  69. Roesler, J., Kofink, B., Wendisch, J., Heyden, S., Paul, D., Friedrich, W., Casanova, J. L., Leupold, W., Gahr, M., Rosen-Wolff, A. (1999) Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options Exp. Hematol. 27,1368-1374[CrossRef][Medline]
    70. 70
  70. Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J. F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., Casanova, J. L. (1996) Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection N. Engl. J. Med. 335,1956-1961[Free Full Text]
    71. 71
  71. Dorman, S. E., Holland, S. M. (1998) Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection J. Clin. Invest. 101,2364-2369[Medline]
    72. 72
  72. Dorman, S. E., Uzel, G., Roesler, J., Bradley, J. S., Bastian, J., Billman, G., King, S., Filie, A., Schermerhorn, J., Holland, S. M. (1999) Viral infections in interferon-gamma receptor deficiency J. Pediatr. 135,640-643[CrossRef][Medline]
    73. 73
  73. Davies, E. G., Isaacs, D., Levinsky, R. J. (1982) Defective immune interferon production and natural killer activity associated with poor neutrophil mobility and delayed umbilical cord separation Clin. Exp. Immunol. 50,454-460[Medline]
    74. 74
  74. Lio, D., Scola, L., Crivello, A., Bonafe, M., Franceschi, C., Olivieri, F., Colonna-Romano, G., Candore, G., Caruso, C. (2002) Allele frequencies of +874T->A single nucleotide polymorphism at the first intron of interferon-gamma gene in a group of Italian centenarians Exp. Gerontol. 37,315-319[CrossRef][Medline]
    75. 75
  75. Espejo, C., Penkowa, M., Saez-Torres, I., Xaus, J., Celada, A., Montalban, X., Martinez-Caceres, E. M. (2001) Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice Exp. Neurol. 172,460-468[CrossRef][Medline]
    76. 76
  76. Billiau, A., Heremans, H., Vandekerckhove, F., Dijkmans, R., Sobis, H., Meulepas, E., Carton, H. (1988) Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma J. Immunol. 140,1506-1510[Abstract]
    77. 77
  77. Heremans, H., Billiau, A., Colombatti, A., Hilgers, J., de Somer, P. (1978) Interferon treatment of NZB mice: accelerated progression of autoimmune disease Infect. Immun. 21,925-930[Abstract/Free Full Text]
    78. 78
  78. Jacob, C. O., McDevitt, H. O. (1988) Tumour necrosis factor-alpha in murine autoimmune ‘lupus’ nephritis Nature 331,356-358[CrossRef][Medline]
    79. 79
  79. Lee, J. Y., Goldman, D., Piliero, L. M., Petri, M., Sullivan, K. E. (2001) Interferon-gamma polymorphisms in systemic lupus erythematosus Genes Immun. 2,254-257[CrossRef][Medline]
    80. 80
  80. Baechler, E. C., Batliwalla, F. M., Karypis, G., Gaffney, P. M., Ortmann, W. A., Espe, K. J., Shark, K. B., Grande, W. J., Hughes, K. M., Kapur, V., Gregersen, P. K., Behrens, T. W. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus Proc. Natl. Acad. Sci. USA 100,2610-2615[Abstract/Free Full Text]
    81. 81
  81. Panitch, H. S., Hirsch, R. L., Haley, A. S., Johnson, K. P. (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon Lancet 1,893-895[Medline]
    82. 82
  82. Sarvetnick, N., Liggitt, D., Pitts, S. L., Hansen, S. E., Stewart, T. A. (1988) Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma Cell 52,773-782[CrossRef][Medline]
    83. 83
  83. Awata, T., Matsumoto, C., Urakami, T., Hagura, R., Amemiya, S., Kanazawa, Y. (1994) Association of polymorphism in the interferon gamma gene with IDDM Diabetologia 37,1159-1162[Medline]
    84. 84
  84. Wang, B., Andre, I., Gonzalez, A., Katz, J. D., Aguet, M., Benoist, C., Mathis, D. (1997) Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes Proc. Natl. Acad. Sci. USA 94,13844-13849[Abstract/Free Full Text]
    85. 85
  85. Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., Schreiber, R. D. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice Proc. Natl. Acad. Sci. USA 95,7556-7561[Abstract/Free Full Text]
    86. 86
  86. Dighe, A. S., Richards, E., Old, L. J., Schreiber, R. D. (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors Immunity 1,447-456[CrossRef][Medline]
    87. 87
  87. Tannenbaum, C. S., Hamilton, T. A. (2000) Immune-inflammatory mechanisms in IFNgamma-mediated anti-tumor activity Semin. Cancer Biol. 10,113-123[CrossRef][Medline]
    88. 88
  88. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., Schreiber, R. D. (2002) Cancer immunoediting: from immunosurveillance to tumor escape Nat. Immunol. 3,991-998[CrossRef][Medline]
    89. 89
  89. Ikeda, H., Old, L. J., Schreiber, R. D. (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting Cytokine Growth Factor Rev. 13,95-109[CrossRef][Medline]
    90. 90
  90. Subramaniam, P. S., Torres, B. A., Johnson, H. M. (2001) So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors Cytokine 15,175-187[CrossRef][Medline]
    91. 91
  91. Sakatsume, M., Igarashi, K., Winestock, K. D., Garotta, G., Larner, A. C., Finbloom, D. S. (1995) The Jak kinases differentially associate with the alpha and beta (accessory factor) chains of the interferon gamma receptor to form a functional receptor unit capable of activating STAT transcription factors J. Biol. Chem. 270,17528-17534[Abstract/Free Full Text]
    92. 92
  92. Marsters, S. A., Pennica, D., Bach, E., Schreiber, R. D., Ashkenazi, A. (1995) Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain Proc. Natl. Acad. Sci. USA 92,5401-5405[Abstract/Free Full Text]
    93. 93
  93. Krause, C. D., Mei, E., Xie, J., Jia, Y., Bopp, M. A., Hochstrasser, R. M., Pestka, S. (2002) Seeing the light: preassembly and ligand-induced changes of the interferon gamma receptor complex in cells Mol. Cell. Proteomics 1,805-815[Abstract/Free Full Text]
    94. 94
  94. Ealick, S. E., Cook, W. J., Vijay-Kumar, S., Carson, M., Nagabhushan, T. L., Trotta, P. P., Bugg, C. E. (1991) Three-dimensional structure of recombinant human interferon-gamma Science 252,698-702[Abstract/Free Full Text]
    95. 95
  95. Walter, M. R., Windsor, W. T., Nagabhushan, T. L., Lundell, D. J., Lunn, C. A., Zauodny, P. J., Narula, S. K. (1995) Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor Nature 376,230-235[CrossRef][Medline]
    96. 96
  96. Fountoulakis, M., Zulauf, M., Lustig, A., Garotta, G. (1992) Stoichiometry of interaction between interferon gamma and its receptor Eur. J. Biochem. 208,781-787[Medline]
    97. 97
  97. Greenlund, A. C., Schreiber, R. D., Goeddel, D. V., Pennica, D. (1993) Interferon-gamma induces receptor dimerization in solution and on cells J. Biol. Chem. 268,18103-18110[Abstract/Free Full Text]
    98. 98
  98. Briscoe, J., Rogers, N. C., Witthuhn, B. A., Watling, D., Harpur, A. G., Wilks, A. F., Stark, G. R., Ihle, J. N., Kerr, I. M. (1996) Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state EMBO J. 15,799-809[Medline]
    99. 99
  99. Igarashi, K., Garotta, G., Ozmen, L., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Larner, A. C., Finbloom, D. S. (1994) Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor J. Biol. Chem. 269,14333-14336[Abstract/Free Full Text]
    100. 100
  100. Greenlund, A. C., Morales, M. O., Viviano, B. L., Yan, H., Krolewski, J., Schreiber, R. D. (1995) Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process Immunity 2,677-687[CrossRef][Medline]
    101. 101
  101. Heim, M. H., Kerr, I. M., Stark, G. R., Darnell, J. E., Jr (1995) Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway Science 267,1347-1349[Abstract/Free Full Text]
    102. 102
  102. Darnell, J. E., Jr, Kerr, I. M., Stark, G. R. (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264,1415-1421[Abstract/Free Full Text]
    103. 103
  103. Schindler, C., Darnell, J. E., Jr (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway Annu. Rev. Biochem. 64,621-651[Medline]
    104. 104
  104. Ramana, C. V., Chatterjee-Kishore, M., Nguyen, H., Stark, G. R. (2000) Complex roles of Stat1 in regulating gene expression Oncogene 19,2619-2627[CrossRef][Medline]
    105. 105
  105. Decker, T., Kovarik, P., Meinke, A. (1997) GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression J. Interferon Cytokine Res. 17,121-134[Medline]
    106. 106
  106. Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., Schreiber, R. D. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway Cell 84,431-442[CrossRef][Medline]
    107. 107
  107. Kerr, I. M., Stark, G. R. (1991) The control of interferon-inducible gene expression FEBS Lett. 285,194-198[CrossRef][Medline]
    108. 108
  108. Paludan, S. R. (1998) Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship Scand. J. Immunol. 48,459-468[CrossRef][Medline]
    109. 109
  109. Chen, X., Vinkemeier, U., Zhao, Y., Jeruzalmi, D., Darnell, J. E., Jr, Kuriyan, J. (1998) Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA Cell 93,827-839[CrossRef][Medline]
    110. 110
  110. Kovarik, P., Stoiber, D., Eyers, P. A., Menghini, R., Neininger, A., Gaestel, M., Cohen, P., Decker, T. (1999) Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway Proc. Natl. Acad. Sci. USA 96,13956-13961[Abstract/Free Full Text]
    111. 111
  111. Goh, K. C., Haque, S. J., Williams, B. R. (1999) p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons EMBO J. 18,5601-5608[CrossRef][Medline]
    112. 112
  112. Wen, Z., Zhong, Z., Darnell, J. E., Jr (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation Cell 82,241-250[CrossRef][Medline]
    113. 113
  113. Zhang, X., Blenis, J., Li, H. C., Schindler, C., Chen-Kiang, S. (1995) Requirement of serine phosphorylation for formation of STAT-promoter complexes Science 267,1990-1994[Abstract/Free Full Text]
    114. 114
  114. Shuai, K., Stark, G. R., Kerr, I. M., Darnell, J. E., Jr (1993) A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma Science 261,1744-1746[Abstract/Free Full Text]
    115. 115
  115. Shuai, K., Horvath, C. M., Huang, L. H., Qureshi, S. A., Cowburn, D., Darnell, J. E., Jr (1994) Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions Cell 76,821-828[CrossRef][Medline]
    116. 116
  116. Matsumoto, M., Tanaka, N., Harada, H., Kimura, T., Yokochi, T., Kitagawa, M., Schindler, C., Taniguchi, T. (1999) Activation of the transcription factor ISGF3 by interferon-gamma Biol. Chem. 380,699-703[CrossRef][Medline]
    117. 117
  117. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., Schreiber, R. D. (1998) How cells respond to interferons Annu. Rev. Biochem. 67,227-264[CrossRef][Medline]
    118. 118
  118. Bluyssen, A. R., Durbin, J. E., Levy, D. E. (1996) ISGF3 gamma p48, a specificity switch for interferon activated transcription factors Cytokine Growth Factor Rev. 7,11-17[CrossRef][Medline]
    119. 119
  119. Chatterjee-Kishore, M., van den Akker, F., Stark, G. R. (2000) Association of STATs with relatives and friends Trends Cell Biol. 10,106-111[CrossRef][Medline]
    120. 120
  120. Decker, T., Kovarik, P. (2000) Serine phosphorylation of STATs Oncogene 19,2628-2637[CrossRef][Medline]
    121. 121
  121. Zhu, X., Wen, Z., Xu, L. Z., Darnell, J. E., Jr (1997) Stat1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated Jak2 kinase Mol. Cell. Biol. 17,6618-6623[Abstract]
    122. 122
  122. Horvath, C. M., Darnell, J. E., Jr (1996) The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein J. Virol. 70,647-650[Abstract]
    123. 123
  123. Kovarik, P., Stoiber, D., Novy, M., Decker, T. (1998) Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation EMBO J. 17,3660-3668[CrossRef][Medline]
    124. 124
  124. Gollob, J. A., Schnipper, C. P., Murphy, E. A., Ritz, J., Frank, D. A. (1999) The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation J. Immunol. 162,4472-4481[Abstract/Free Full Text]
    125. 125
  125. Singh, K., Balligand, J. L., Fischer, T. A., Smith, T. W., Kelly, R. A. (1996) Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells. Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha J. Biol. Chem. 271,1111-1117[Abstract/Free Full Text]
    126. 126
  126. Chan, E. D., Riches, D. W. (2001) IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line Am. J. Physiol. Cell Physiol. 280,C441-C450[Abstract/Free Full Text]
    127. 127
  127. Mahboubi, K., Pober, J. S. (2002) Activation of signal transducer and activator of transcription 1 (STAT1) is not sufficient for the induction of STAT1-dependent genes in endothelial cells. Comparison of interferon-gamma and oncostatin M J. Biol. Chem. 277,8012-8021[Abstract/Free Full Text]
    128. 128
  128. Ouchi, T., Lee, S. W., Ouchi, M., Aaronson, S. A., Horvath, C. M. (2000) Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes Proc. Natl. Acad. Sci. USA 97,5208-5213[Abstract/Free Full Text]
    129. 129
  129. Zhang, J. J., Zhao, Y., Chait, B. T., Lathem, W. W., Ritzi, M., Knippers, R., Darnell, J. E., Jr (1998) Ser727-dependent recruitment of MCM5 by Stat1alpha in IFN-gamma-induced transcriptional activation EMBO J. 17,6963-6971[CrossRef][Medline]
    130. 130
  130. Vinkemeier, U., Cohen, S. L., Moarefi, I., Chait, B. T., Kuriyan, J., Darnell, J. E., Jr (1996) DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites EMBO J. 15,5616-5626[Medline]
    131. 131
  131. Xu, X., Sun, Y. L., Hoey, T. (1996) Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain Science 273,794-797[Abstract]
    132. 132
  132. Kumar, A., Commane, M., Flickinger, T. W., Horvath, C. M., Stark, G. R. (1997) Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases Science 278,1630-1632[Abstract/Free Full Text]
    133. 133
  133. Lee, C. K., Smith, E., Gimeno, R., Gertner, R., Levy, D. E. (2000) STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma J. Immunol. 164,1286-1292[Abstract/Free Full Text]
    134. 134
  134. Chatterjee-Kishore, M., Wright, K. L., Ting, J. P., Stark, G. R. (2000) How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene EMBO J. 19,4111-4122[CrossRef][Medline]
    135. 135
  135. Sekimoto, T., Imamoto, N., Nakajima, K., Hirano, T., Yoneda, Y. (1997) Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1 EMBO J. 16,7067-7077[CrossRef][Medline]
    136. 136
  136. Lillemeier, B. F., Koster, M., Kerr, I. M. (2001) STAT1 from the cell membrane to the DNA EMBO J. 20,2508-2517[CrossRef][Medline]
    137. 137
  137. McBride, K. M., McDonald, C., Reich, N. C. (2000) Nuclear export signal located within the DNA-binding domain of the STAT1 transcription factor EMBO J. 19,6196-6206[CrossRef][Medline]
    138. 138
  138. Koster, M., Hauser, H. (1999) Dynamic redistribution of STAT1 protein in IFN signaling visualized by GFP fusion proteins Eur. J. Biochem. 260,137-144[Medline]
    139. 139
  139. Dingwall, C., Laskey, R. A. (1991) Nuclear targeting sequences–a consensus? Trends Biochem. Sci. 16,478-481[CrossRef][Medline]
    140. 140
  140. MacDonald, H. S., Kushnaryov, V. M., Sedmak, J. J., Grossberg, S. E. (1986) Transport of gamma-interferon into the cell nucleus may be mediated by nuclear membrane receptors Biochem. Biophys. Res. Commun. 138,254-260[CrossRef][Medline]
    141. 141
  141. Bader, T., Weitzerbin, J. (1994) Nuclear accumulation of interferon gamma Proc. Natl. Acad. Sci. USA 91,11831-11835[Abstract/Free Full Text]
    142. 142
  142. Subramaniam, P. S., Mujtaba, M. G., Paddy, M. R., Johnson, H. M. (1999) The carboxyl terminus of interferon-gamma contains a functional polybasic nuclear localization sequence J. Biol. Chem. 274,403-407[Abstract/Free Full Text]
    143. 143
  143. Subramaniam, P. S., Larkin, J., III, Mujtaba, M. G., Walter, M. R., Johnson, H. M. (2000) The COOH-terminal nuclear localization sequence of interferon gamma regulates STAT1 alpha nuclear translocation at an intracellular site J. Cell Sci. 113,2771-2781[Abstract]
    144. 144
  144. Wetzel, R., Perry, L. J., Veilleux, C., Chang, G. (1990) Mutational analysis of the C-terminus of human interferon-gamma Protein Eng. 3,611-623[Abstract/Free Full Text]
    145. 145
  145. Lundell, D., Lunn, C., Dalgarno, D., Fossetta, J., Greenberg, R., Reim, R., Grace, M., Narula, S. (1991) The carboxyl-terminal region of human interferon gamma is important for biological activity: mutagenic and NMR analysis Protein Eng. 4,335-341[Abstract/Free Full Text]
    146. 146
  146. Fidler, I. J., Fogler, W. E., Kleinerman, E. S., Saiki, I. (1985) Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes J. Immunol. 135,4289-4296[Abstract]
    147. 147
  147. Sanceau, J., Sondermeyer, P., Beranger, F., Falcoff, R., Vaquero, C. (1987) Intracellular human gamma-interferon triggers an antiviral state in transformed murine L cells Proc. Natl. Acad. Sci. USA 84,2906-2910[Abstract/Free Full Text]
    148. 148
  148. Smith, M. R., Muegge, K., Keller, J. R., Kung, H. F., Young, H. A., Durum, S. K. (1990) Direct evidence for an intracellular role for IFN-gamma. Microinjection of human IFN-gamma induces Ia expression on murine macrophages J. Immunol. 144,1777-1782[Abstract]
    149. 149
  149. Subramaniam, P. S., Green, M. M., Larkin, J., III, Torres, B. A., Johnson, H. M. (2001) Nuclear translocation of IFN-gamma is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence J. Interferon Cytokine Res. 21,951-959[CrossRef][Medline]
    150. 150
  150. Larkin, J., III, Johnson, H. M., Subramaniam, P. S. (2000) Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-gamma receptor complex following activation by IFN-gamma J. Interferon Cytokine Res. 20,565-576[CrossRef][Medline]
    151. 151
  151. Durbin, J. E., Hackenmiller, R., Simon, M. C., Levy, D. E. (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease Cell 84,443-450[CrossRef][Medline]
    152. 152
  152. Ramana, C. V., Gil, M. P., Han, Y., Ransohoff, R. M., Schreiber, R. D., Stark, G. R. (2001) Stat1-independent regulation of gene expression in response to IFN-gamma Proc. Natl. Acad. Sci. USA 98,6674-6679[Abstract/Free Full Text]
    153. 153
  153. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., Darnell, J. E., Jr (1996) Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma Proc. Natl. Acad. Sci. USA 93,7673-7678[Abstract/Free Full Text]
    154. 154
  154. Ramana, C. V., Grammatikakis, N., Chernov, M., Nguyen, H., Goh, K. C., Williams, B. R., Stark, G. R. (2000) Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways EMBO J. 19,263-272[CrossRef][Medline]
    155. 155
  155. Gil, M. P., Bohn, E., O’Guin, A. K., Ramana, C. V., Levine, B., Stark, G. R., Virgin, H. W., Schreiber, R. D. (2001) Biologic consequences of Stat1-independent IFN signaling Proc. Natl. Acad. Sci. USA 98,6680-6685[Abstract/Free Full Text]
    156. 156
  156. Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S., Harris, J., Holland, S. M., Schreiber, R. D., Casanova, J. L. (2001) Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation Science 293,300-303[Abstract/Free Full Text]
    157. 157
  157. Taniguchi, T., Ogasawara, K., Takaoka, A., Tanaka, N. (2001) IRF family of transcription factors as regulators of host defense Annu. Rev. Immunol. 19,623-655[CrossRef][Medline]
    158. 158
  158. Sims, S. H., Cha, Y., Romine, M. F., Gao, P. Q., Gottlieb, K., Deisseroth, A. B. (1993) A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter Mol. Cell. Biol. 13,690-702[Abstract/Free Full Text]
    159. 159
  159. Harada, H., Takahashi, E., Itoh, S., Harada, K., Hori, T. A., Taniguchi, T. (1994) Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system Mol. Cell. Biol. 14,1500-1509[Abstract/Free Full Text]
    160. 160
  160. Pine, R. (1997) Convergence of TNFalpha and IFNgamma signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter element Nucleic Acids Res. 25,4346-4354[Abstract/Free Full Text]
    161. 161
  161. Mamane, Y., Heylbroeck, C., Genin, P., Algarte, M., Servant, M. J., LePage, C., DeLuca, C., Kwon, H., Lin, R., Hiscott, J. (1999) Interferon regulatory factors: the next generation Gene 237,1-14[CrossRef][Medline]
    162. 162
  162. Salkowski, C. A., Kopydlowski, K., Blanco, J., Cody, M. J., McNally, R., Vogel, S. N. (1999) IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice J. Immunol. 163,1529-1536[Abstract/Free Full Text]
    163. 163
  163. Hobart, M., Ramassar, V., Goes, N., Urmson, J., Halloran, P. F. (1996) The induction of class I and II major histocompatibility complex by allogeneic stimulation is dependent on the transcription factor interferon regulatory factor 1 (IRF-1): observations in IRF-1 knockout mice Transplantation 62,1895-1901[CrossRef][Medline]
    164. 164
  164. Tanaka, N., Kawakami, T., Taniguchi, T. (1993) Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system Mol. Cell. Biol. 13,4531-4538[Abstract/Free Full Text]
    165. 165
  165. Tanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M. S., Aizawa, S., Mak, T. W., Taniguchi, T. (1994) Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 Cell 77,829-839[CrossRef][Medline]
    166. 166
  166. Kimura, T., Nakayama, K., Penninger, J., Kitagawa, M., Harada, H., Matsuyama, T., Tanaka, N., Kamijo, R., Vilcek, J., Mak, T. W., et al (1994) Involvement of the IRF-1 transcription factor in antiviral responses to interferons Science 264,1921-1924[Abstract/Free Full Text]
    167. 167
  167. Ohmori, Y., Hamilton, T. A. (1994) IFN-gamma selectively inhibits lipopolysaccharide-inducible JE/monocyte chemoattractant protein-1 and KC/GRO/melanoma growth-stimulating activity gene expression in mouse peritoneal macrophages J. Immunol. 153,2204-2212[Abstract]
    168. 168
  168. Cook, J. R., Emanuel, S. L., Donnelly, R. J., Soh, J., Mariano, T. M., Schwartz, B., Rhee, S., Pestka, S. (1994) Sublocalization of the human interferon-gamma receptor accessory factor gene and characterization of accessory factor activity by yeast artificial chromosomal fragmentation J. Biol. Chem. 269,7013-7018[Abstract/Free Full Text]
    169. 169
  169. Darnell, J. E., Jr (1997) STATs and gene regulation Science 277,1630-1635[Abstract/Free Full Text]
    170. 170
  170. Schreiber, R. D., Farrar, M. A. (1993) The biology and biochemistry of interferon-gamma and its receptor Gastroenterol Jpn 28(Suppl. 4),88-94
    171. 171
  171. Anderson, P., Yip, Y. K., Vilcek, J. (1983) Human interferon-gamma is internalized and degraded by cultured fibroblasts J. Biol. Chem. 258,6497-6502[Abstract/Free Full Text]
    172. 172
  172. Celada, A., Schreiber, R. D. (1987) Internalization and degradation of receptor-bound interferon-gamma by murine macrophages. Demonstration of receptor recycling J. Immunol. 139,147-153[Abstract]
    173. 173
  173. Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., Miyazaki, T., Leonor, N., Taniguchi, T., Fujita, T., Kanakura, Y., Komiya, S., Yoshimura, A. (1997) A new protein containing an SH2 domain that inhibits JAK kinases Nature 387,921-924[CrossRef][Medline]
    174. 174
  174. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., Hilton, D. J. (1997) A family of cytokine-inducible inhibitors of signalling Nature 387,917-921[CrossRef][Medline]
    175. 175
  175. Suzuki, R., Sakamoto, H., Yasukawa, H., Masuhara, M., Wakioka, T., Sasaki, A., Yuge, K., Komiya, S., Inoue, A., Yoshimura, A. (1998) CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells Oncogene 17,2271-2278[CrossRef][Medline]
    176. 176
  176. Sakamoto, H., Yasukawa, H., Masuhara, M., Tanimura, S., Sasaki, A., Yuge, K., Ohtsubo, M., Ohtsuka, A., Fujita, T., Ohta, T., Furukawa, Y., Iwase, S., Yamada, H., Yoshimura, A. (1998) A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons Blood 92,1668-1676[Abstract/Free Full Text]
    177. 177
  177. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N., Yoshimura, A. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop EMBO J. 18,1309-1320[CrossRef][Medline]
    178. 178
  178. Zhang, J. G., Farley, A., Nicholson, S. E., Willson, T. A., Zugaro, L. M., Simpson, R. J., Moritz, R. L., Cary, D., Richardson, R., Hausmann, G., Kile, B. J., Kent, S. B., Alexander, W. S., Metcalf, D., Hilton, D. J., Nicola, N. A., Baca, M. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation Proc. Natl. Acad. Sci. USA 96,2071-2076[Abstract/Free Full Text]
    179. 179
  179. Fujimoto, M., Naka, T., Nakagawa, R., Kawazoe, Y., Morita, Y., Tateishi, A., Okumura, K., Narazaki, M., Kishimoto, T. (2000) Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice J. Immunol. 165,1799-1806[Abstract/Free Full Text]
    180. 180
  180. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., Kay, T. W., Nicola, N. A., Hertzog, P. J., Metcalf, D., Hilton, D. J. (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine Cell 98,597-608[CrossRef][Medline]
    181. 181
  181. Marine, J. C., Topham, D. J., McKay, C., Wang, D., Parganas, E., Stravopodis, D., Yoshimura, A., Ihle, J. N. (1999) SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality Cell 98,609-616[CrossRef][Medline]
    182. 182
  182. Song, M. M., Shuai, K. (1998) The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities J. Biol. Chem. 273,35056-35062[Abstract/Free Full Text]
    183. 183
  183. Haque, S. J., Wu, Q., Kammer, W., Friedrich, K., Smith, J. M., Kerr, I. M., Stark, G. R., Williams, B. R. (1997) Receptor-associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1 Proc. Natl. Acad. Sci. USA 94,8563-8568[Abstract/Free Full Text]
    184. 184
  184. You, M., Yu, D. H., Feng, G. S. (1999) Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway Mol. Cell. Biol. 19,2416-2424[Abstract/Free Full Text]
    185. 185
  185. Ruff, S. J., Chen, K., Cohen, S. (1997) Peroxovanadate induces tyrosine phosphorylation of multiple signaling proteins in mouse liver and kidney J. Biol. Chem. 272,1263-1267[Abstract/Free Full Text]
    186. 186
  186. David, M., Chen, H. E., Goelz, S., Larner, A. C., Neel, B. G. (1995) Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1 Mol. Cell. Biol. 15,7050-7058[Abstract]
    187. 187
  187. Yu, C. L., Jin, Y. J., Burakoff, S. J. (2000) Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation J. Biol. Chem. 275,599-604[Abstract/Free Full Text]
    188. 188
  188. Shultz, L. D., Schweitzer, P. A., Rajan, T. V., Yi, T., Ihle, J. N., Matthews, R. J., Thomas, M. L., Beier, D. R. (1993) Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene Cell 73,1445-1454[CrossRef][Medline]
    189. 189
  189. Mowen, K., David, M. (2000) Regulation of STAT1 nuclear export by Jak1 Mol. Cell. Biol. 20,7273-7281[Abstract/Free Full Text]
    190. 190
  190. Fornerod, M., Ohno, M., Yoshida, M., Mattaj, I. W. (1997) CRM1 is an export receptor for leucine-rich nuclear export signals Cell 90,1051-1060[CrossRef][Medline]
    191. 191
  191. Stade, K., Ford, C. S., Guthrie, C., Weis, K. (1997) Exportin 1 (Crm1p) is an essential nuclear export factor Cell 90,1041-1050[CrossRef][Medline]
    192. 192
  192. Haspel, R. L., Darnell, J. E., Jr (1999) A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1 Proc. Natl. Acad. Sci. USA 96,10188-10193[Abstract/Free Full Text]
    193. 193
  193. Haspel, R. L., Salditt-Georgieff, M., Darnell, J. E., Jr (1996) The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase EMBO J. 15,6262-6268[Medline]
    194. 194
  194. Muller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A. G., Barbieri, G., Witthuhn, B. A., Schindler, C., et al (1993) The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction Nature 366,129-135[CrossRef][Medline]
    195. 195
  195. Watling, D., Guschin, D., Muller, M., Silvennoinen, O., Witthuhn, B. A., Quelle, F. W., Rogers, N. C., Schindler, C., Stark, G. R., Ihle, J. N., et al (1993) Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway Nature 366,166-170[CrossRef][Medline]
    196. 196
  196. Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C., Yin, L., Pennica, D., Johnson, E. M., Jr, Schreiber, R. D. (1998) Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses Cell 93,373-383[CrossRef][Medline]
    197. 197
  197. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J. C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., Grosveld, G., Ihle, J. N. (1998) Jak2 is essential for signaling through a variety of cytokine receptors Cell 93,385-395[CrossRef][Medline]
    198. 198
  198. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., Pfeffer, K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis Cell 93,397-409[CrossRef][Medline]
    199. 199
  199. Kotenko, S. V., Izotova, L. S., Pollack, B. P., Muthukumaran, G., Paukku, K., Silvennoinen, O., Ihle, J. N., Pestka, S. (1996) Other kinases can substitute for Jak2 in signal transduction by interferon-gamma J. Biol. Chem. 271,17174-17182[Abstract/Free Full Text]
    200. 200
  200. Kaplan, M. H., Sun, Y. L., Hoey, T., Grusby, M. J. (1996) Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice Nature 382,174-177[CrossRef][Medline]
    201. 201
  201. Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A., Doherty, P. C., Grosveld, G. C., Ihle, J. N. (1996) Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells Nature 382,171-174[CrossRef][Medline]
    202. 202
  202. Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., Nakanishi, K., Yoshida, N., Kishimoto, T., Akira, S. (1996) Essential role of Stat6 in IL-4 signalling Nature 380,627-630[CrossRef][Medline]
    203. 203
  203. Shimoda, K., van Deursen, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, C., Quelle, F. W., Nosaka, T., Vignali, D. A., Doherty, P. C., Grosveld, G., Paul, W. E., Ihle, J. N. (1996) Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene Nature 380,630-633[CrossRef][Medline]
    204. 204
  204. Liu, X., Robinson, G. W., Wagner, K. U., Garrett, L., Wynshaw-Boris, A., Hennighausen, L. (1997) Stat5a is mandatory for adult mammary gland development and lactogenesis Genes Dev. 11,179-186[Abstract/Free Full Text]
    205. 205
  205. Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., Akira, S. (1998) Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice J. Immunol. 161,4652-4660[Abstract/Free Full Text]
    206. 206
  206. Kawakami, T., Matsumoto, M., Sato, M., Harada, H., Taniguchi, T., Kitagawa, M. (1995) Possible involvement of the transcription factor ISGF3 gamma in virus-induced expression of the IFN-beta gene FEBS Lett. 358,225-229[CrossRef][Medline]
    207. 207
  207. Yoneyama, M., Suhara, W., Fukuhara, Y., Sato, M., Ozato, K., Fujita, T. (1996) Autocrine amplification of type I interferon gene expression mediated by interferon stimulated gene factor 3 (ISGF3) J. Biochem. (Tokyo) 120,160-169[Abstract/Free Full Text]
    208. 208
  208. Min, W., Pober, J. S., Johnson, D. R. (1998) Interferon induction of TAP1: the phosphatase SHP-1 regulates crossover between the IFN-alpha/beta and the IFN-gamma signal-transduction pathways Circ. Res. 83,815-823[Abstract/Free Full Text]
    209. 209
  209. Takaoka, A., Mitani, Y., Suemori, H., Sato, M., Yokochi, T., Noguchi, S., Tanaka, N., Taniguchi, T. (2000) Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains Science 288,2357-2360[Abstract/Free Full Text]
    210. 210
  210. Belich, M. P., Glynne, R. J., Senger, G., Sheer, D., Trowsdale, J. (1994) Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins Curr. Biol. 4,769-776[CrossRef][Medline]
    211. 211
  211. Kelly, A., Powis, S. H., Glynne, R., Radley, E., Beck, S., Trowsdale, J. (1991) Second proteasome-related gene in the human MHC class II region Nature 353,667-668[CrossRef][Medline]
    212. 212
  212. Groettrup, M., Kraft, R., Kostka, S., Standera, S., Stohwasser, R., Kloetzel, P. M. (1996) A third interferon-gamma-induced subunit exchange in the 20S proteasome Eur. J. Immunol. 26,863-869[Medline]
    213. 213
  213. Nandi, D., Jiang, H., Monaco, J. J. (1996) Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit J. Immunol. 156,2361-2364[Abstract]
    214. 214
  214. Hisamatsu, H., Shimbara, N., Saito, Y., Kristensen, P., Hendil, K. B., Fujiwara, T., Takahashi, E., Tanahashi, N., Tamura, T., Ichihara, A., Tanaka, K. (1996) Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma J. Exp. Med. 183,1807-1816[Abstract/Free Full Text]
    215. 215
  215. Strobl, B., Arulampalam, V., Is’harc, H., Newman, S. J., Schlaak, J. F., Watling, D., Costa-Pereira, A. P., Schaper, F., Behrmann, I., Sheehan, K. C., Schreiber, R. D., Horn, F., Heinrich, P. C., Kerr, I. M. (2001) A completely foreign receptor can mediate an interferon-gamma-like response EMBO J. 20,5431-5442[CrossRef][Medline]
    216. 216
  216. Groettrup, M., Khan, S., Schwarz, K., Schmidtke, G. (2001) Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie 83,367-372[Medline]
    217. 217
  217. Dick, T. P., Ruppert, T., Groettrup, M., Kloetzel, P. M., Kuehn, L., Koszinowski, U. H., Stevanovic, S., Schild, H., Rammensee, H. G. (1996) Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands Cell 86,253-262[CrossRef][Medline]
    218. 218
  218. Groettrup, M., Soza, A., Eggers, M., Kuehn, L., Dick, T. P., Schild, H., Rammensee, H. G., Koszinowski, U. H., Kloetzel, P. M. (1996) A role for the proteasome regulator PA28alpha in antigen presentation Nature 381,166-168[CrossRef][Medline]
    219. 219
  219. Boes, B., Hengel, H., Ruppert, T., Multhaup, G., Koszinowski, U. H., Kloetzel, P. M. (1994) Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes J. Exp. Med. 179,901-909[Abstract/Free Full Text]
    220. 220
  220. Trowsdale, J., Hanson, I., Mockridge, I., Beck, S., Townsend, A., Kelly, A. (1990) Sequences encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters Nature 348,741-744[CrossRef][Medline]
    221. 221
  221. Epperson, D. E., Arnold, D., Spies, T., Cresswell, P., Pober, J. S., Johnson, D. R. (1992) Cytokines increase transporter in antigen processing-1 expression more rapidly than HLA class I expression in endothelial cells J. Immunol. 149,3297-3301[Abstract]
    222. 222
  222. Decker, T., Stockinger, S., Karaghiosoff, M., Muller, M., Kovarik, P. (2002) IFNs and STATs in innate immunity to microorganisms J. Clin. Invest. 109,1271-1277[CrossRef][Medline]
    223. 223
  223. Cramer, L. A., Nelson, S. L., Klemsz, M. J. (2000) Synergistic induction of the Tap-1 gene by IFN-gamma and lipopolysaccharide in macrophages is regulated by STAT1 J. Immunol. 165,3190-3197[Abstract/Free Full Text]
    224. 224
  224. Shirayoshi, Y., Burke, P. A., Appella, E., Ozato, K. (1988) Interferon-induced transcription of a major histocompatibility class I gene accompanies binding of inducible nuclear factors to the interferon consensus sequence Proc. Natl. Acad. Sci. USA 85,5884-5888[Abstract/Free Full Text]
    225. 225
  225. Pestka, S., Langer, J. A., Zoon, K. C., Samuel, C. E. (1987) Interferons and their actions Annu. Rev. Biochem. 56,727-777[CrossRef][Medline]
    226. 226
  226. Scheurich, P., Kronke, M., Schluter, C., Ucer, U., Pfizenmaier, K. (1986) Noncytocidal mechanisms of action of tumor necrosis factor-alpha on human tumor cells: enhancement of HLA gene expression synergistic with interferon-gamma Immunobiology 172,291-300[Medline]
    227. 227
  227. Johnson, D. R., Pober, J. S. (1990) Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium Proc. Natl. Acad. Sci. USA 87,5183-5187[Abstract/Free Full Text]
    228. 228
  228. Reis, L. F., Harada, H., Wolchok, J. D., Taniguchi, T., Vilcek, J. (1992) Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes EMBO J. 11,185-193[Medline]
    229. 229
  229. Chang, C. H., Hammer, J., Loh, J. E., Fodor, W. L., Flavell, R. A. (1992) The activation of major histocompatibility complex class I genes by interferon regulatory factor-1 (IRF-1) Immunogenetics 35,378-384[Medline]
    230. 230
  230. Wallach, D., Fellous, M., Revel, M. (1982) Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells Nature 299,833-836[CrossRef][Medline]
    231. 231
  231. Fellous, M., Nir, U., Wallach, D., Merlin, G., Rubinstein, M., Revel, M. (1982) Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells Proc. Natl. Acad. Sci. USA 79,3082-3086[Abstract/Free Full Text]
    232. 232
  232. Seder, R. A., Gazzinelli, R. T. (1999) Cytokines are critical in linking the innate and adaptive immune responses to bacterial, fungal, and parasitic infection Adv. Intern. Med. 44,353-388[Medline]
    233. 233
  233. Seliger, B., Schreiber, K., Delp, K., Meissner, M., Hammers, S., Reichert, T., Pawlischko, K., Tampe, R., Huber, C. (2001) Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines Tissue Antigens 57,39-45[CrossRef][Medline]
    234. 234
  234. Mach, B., Steimle, V., Martinez-Soria, E., Reith, W. (1996) Regulation of MHC class II genes: lessons from a disease Annu. Rev. Immunol. 14,301-331[CrossRef][Medline]
    235. 235
  235. Kern, I., Steimle, V., Siegrist, C. A., Mach, B. (1995) The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes Int. Immunol. 7,1295-1299[Abstract/Free Full Text]
    236. 236
  236. Figueiredo, F., Koerner, T. J., Adams, D. O. (1989) Molecular mechanisms regulating the expression of class II histocompatibility molecules on macrophages. Effects of inductive and suppressive signals on gene transcription J. Immunol. 143,3781-3786[Abstract]
    237. 237
  237. Chang, C. H., Flavell, R. A. (1995) Class II transactivator regulates the expression of multiple genes involved in antigen presentation J. Exp. Med. 181,765-767[Abstract/Free Full Text]
    238. 238
  238. Cresswell, P. (1994) Assembly, transport, and function of MHC class II molecules Annu. Rev. Immunol. 12,259-293[CrossRef][Medline]
    239. 239
  239. Wolf, P. R., Ploegh, H. L. (1995) How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway Annu. Rev. Cell Dev. Biol. 11,267-306[CrossRef][Medline]
    240. 240
  240. Lah, T. T., Hawley, M., Rock, K. L., Goldberg, A. L. (1995) Gamma-interferon causes a selective induction of the lysosomal proteases, cathepsins B and L, in macrophages FEBS Lett. 363,85-89[CrossRef][Medline]
    241. 241
  241. Lafuse, W. P., Brown, D., Castle, L., Zwilling, B. S. (1995) IFN-gamma increases cathepsin H mRNA levels in mouse macrophages J. Leukoc. Biol. 57,663-669[Abstract]
    242. 242
  242. Meurs, E., Chong, K., Galabru, J., Thomas, N. S., Kerr, I. M., Williams, B. R., Hovanessian, A. G. (1990) Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon Cell 62,379-390[CrossRef][Medline]
    243. 243
  243. Zamanian-Daryoush, M., Mogensen, T. H., DiDonato, J. A., Williams, B. R. (2000) NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase Mol. Cell. Biol. 20,1278-1290[Abstract/Free Full Text]
    244. 244
  244. Osman, F., Jarrous, N., Ben-Asouli, Y., Kaempfer, R. (1999) A cis-acting element in the 3'-untranslated region of human TNF-alpha mRNA renders splicing dependent on the activation of protein kinase PKR Genes Dev. 13,3280-3293[Abstract/Free Full Text]
    245. 245
  245. Donze, O., Dostie, J., Sonenberg, N. (1999) Regulatable expression of the interferon-induced double-stranded RNA dependent protein kinase PKR induces apoptosis and fas receptor expression Virology 256,322-329[CrossRef][Medline]
    246. 246
  246. Balachandran, S., Kim, C. N., Yeh, W. C., Mak, T. W., Bhalla, K., Barber, G. N. (1998) Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling EMBO J. 17,6888-6902[CrossRef][Medline]
    247. 247
  247. Wong, A. H., Tam, N. W., Yang, Y. L., Cuddihy, A. R., Li, S., Kirchhoff, S., Hauser, H., Decker, T., Koromilas, A. E. (1997) Physical association between STAT1 and the interferon-inducible protein kinase PKR and implications for interferon and double-stranded RNA signaling pathways EMBO J. 16,1291-1304[CrossRef][Medline]
    248. 248
  248. Patterson, J. B., Thomis, D. C., Hans, S. L., Samuel, C. E. (1995) Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons Virology 210,508-511[CrossRef][Medline]
    249. 249
  249. Anderson, S. L., Carton, J. M., Lou, J., Xing, L., Rubin, B. Y. (1999) Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus Virology 256,8-14[CrossRef][Medline]
    250. 250
  250. Vestal, D. J., Gorbacheva, V. Y., Sen, G. C. (2000) Different subcellular localizations for the related interferon-induced GTPases, MuGBP-1 and MuGBP-2: implications for different functions? J. Interferon Cytokine Res. 20,991-1000[CrossRef][Medline]
    251. 251
  251. Raveh, T., Hovanessian, A. G., Meurs, E. F., Sonenberg, N., Kimchi, A. (1996) Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons J. Biol. Chem. 271,25479-25484[Abstract/Free Full Text]
    252. 252
  252. Xaus, J., Cardo, M., Valledor, A. F., Soler, C., Lloberas, J., Celada, A. (1999) Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis Immunity 11,103-113[CrossRef][Medline]
    253. 253
  253. Harvat, B. L., Seth, P., Jetten, A. M. (1997) The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells Oncogene 14,2111-2122[CrossRef][Medline]
    254. 254
  254. Matsuoka, M., Nishimoto, I., Asano, S. (1999) Interferon-gamma impairs physiologic downregulation of cyclin-dependent kinase inhibitor, p27Kip1, during G1 phase progression in macrophages Exp. Hematol. 27,203-209[CrossRef][Medline]
    255. 255
  255. Kominsky, S., Johnson, H. M., Bryan, G., Tanabe, T., Hobeika, A. C., Subramaniam, P. S., Torres, B. (1998) IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1 Oncogene 17,2973-2979[CrossRef][Medline]
    256. 256
  256. Mandal, M., Bandyopadhyay, D., Goepfert, T. M., Kumar, R. (1998) Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK) Oncogene 16,217-225[CrossRef][Medline]
    257. 257
  257. Harvat, B. L., Jetten, A. M. (1996) Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma Cell Growth Differ. 7,289-300[Abstract]
    258. 258
  258. Choubey, D., Gutterman, J. U. (1997) Inhibition of E2F-4/DP-1-stimulated transcription by p202 Oncogene 15,291-301[CrossRef][Medline]
    259. 259
  259. Ayer, D. E., Kretzner, L., Eisenman, R. N. (1993) Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity Cell 72,211-222[CrossRef][Medline]
    260. 260
  260. Ayer, D. E., Eisenman, R. N. (1993) A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation Genes Dev. 7,2110-2119[Abstract/Free Full Text]
    261. 261
  261. Cultraro, C. M., Bino, T., Segal, S. (1997) Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation Mol. Cell. Biol. 17,2353-2359[Abstract]
    262. 262
  262. Vastrik, I., Kaipainen, A., Penttila, T. L., Lymboussakis, A., Alitalo, R., Parvinen, M., Alitalo, K. (1995) Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro J. Cell Biol. 128,1197-1208[Abstract/Free Full Text]
    263. 263
  263. Obaya, A. J., Mateyak, M. K., Sedivy, J. M. (1999) Mysterious liaisons: the relationship between c-Myc and the cell cycle Oncogene 18,2934-2941[CrossRef][Medline]
    264. 264
  264. Vairo, G., Vadiveloo, P. K., Royston, A. K., Rockman, S. P., Rock, C. O., Jackowski, S., Hamilton, J. A. (1995) Deregulated c-myc expression overrides IFN gamma-induced macrophage growth arrest Oncogene 10,1969-1976[Medline]
    265. 265
  265. Grandori, C., Eisenman, R. N. (1997) Myc target genes Trends Biochem. Sci. 22,177-181[CrossRef][Medline]
    266. 266
  266. Taniguchi, T., Lamphier, M. S., Tanaka, N. (1997) IRF-1: the transcription factor linking the interferon response and oncogenesis Biochim. Biophys. Acta 1333,M9-M17[Medline]
    267. 267
  267. Tamura, T., Ishihara, M., Lamphier, M. S., Tanaka, N., Oishi, I., Aizawa, S., Matsuyama, T., Mak, T. W., Taki, S., Taniguchi, T. (1997) DNA damage-induced apoptosis and ice gene induction in mitogenically activated T lymphocytes require IRF-1 Leukemia 11(Suppl. 3),439-440
    268. 268
  268. Villa, P., Kaufmann, S. H., Earnshaw, W. C. (1997) Caspases and caspase inhibitors Trends Biochem. Sci. 22,388-393[CrossRef][Medline]
    269. 269
  269. Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A., Fu, X. Y. (1997) Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis Mol. Cell. Biol. 17,5328-5337[Abstract]
    270. 270
  270. Takizawa, T., Ohashi, K., Nakanishi, Y. (1996) Possible involvement of double-stranded RNA-activated protein kinase in cell death by influenza virus infection J. Virol. 70,8128-8132[Abstract]
    271. 271
  271. Yeung, M. C., Liu, J., Lau, A. S. (1996) An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells Proc. Natl. Acad. Sci. USA 93,12451-12455[Abstract/Free Full Text]
    272. 272
  272. Lee, S. B., Esteban, M. (1994) The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis Virology 199,491-496[CrossRef][Medline]
    273. 273
  273. Inbal, B., Cohen, O., Polak-Charcon, S., Kopolovic, J., Vadai, E., Eisenbach, L., Kimchi, A. (1997) DAP kinase links the control of apoptosis to metastasis Nature 390,180-184[CrossRef][Medline]
    274. 274
  274. Deiss, L. P., Feinstein, E., Berissi, H., Cohen, O., Kimchi, A. (1995) Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death Genes Dev. 9,15-30[Abstract/Free Full Text]
    275. 275
  275. Kissil, J. L., Deiss, L. P., Bayewitch, M., Raveh, T., Khaspekov, G., Kimchi, A. (1995) Isolation of DAP3, a novel mediator of interferon-gamma-induced cell death J. Biol. Chem. 270,27932-27936[Abstract/Free Full Text]
    276. 276
  276. Levy-Strumpf, N., Deiss, L. P., Berissi, H., Kimchi, A. (1997) DAP-5, a novel homolog of eukaryotic translation initiation factor 4G isolated as a putative modulator of gamma interferon-induced programmed cell death Mol. Cell. Biol. 17,1615-1625[Abstract]
    277. 277
  277. Deiss, L. P., Galinka, H., Berissi, H., Cohen, O., Kimchi, A. (1996) Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha EMBO J. 15,3861-3870[Medline]
    278. 278
  278. Xu, X., Fu, X. Y., Plate, J., Chong, A. S. (1998) IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression Cancer Res. 58,2832-2837[Abstract/Free Full Text]
    279. 279
  279. Zheng, H., Luo, R. C., Zhang, L. S., Mai, G. F. (2002) Interferon-gamma up-regulates Fas expression and increases Fas-mediated apoptosis in tumor cell lines Di Yi Jun Yi Da Xue Xue Bao 22,1090-1092[Medline]
    280. 280
  280. Tsujimoto, M., Yip, Y. K., Vilcek, J. (1986) Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor J. Immunol. 136,2441-2444[Abstract]
    281. 281
  281. MacMicking, J., Xie, Q. W., Nathan, C. (1997) Nitric oxide and macrophage function Annu. Rev. Immunol. 15,323-350[CrossRef][Medline]
    282. 282
  282. Eizirik, D. L., Flodstrom, M., Karlsen, A. E., Welsh, N. (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells Diabetologia 39,875-890[Medline]
    283. 283
  283. Kawahara, K., Gotoh, T., Oyadomari, S., Kajizono, M., Kuniyasu, A., Ohsawa, K., Imai, Y., Kohsaka, S., Nakayama, H., Mori, M. (2001) Co-induction of argininosuccinate synthetase, cationic amino acid transporter-2, and nitric oxide synthase in activated murine microglial cells Brain Res. Mol. Brain Res. 90,165-173[Medline]
    284. 284
  284. Nussler, A. K., Billiar, T. R., Liu, Z. Z., Morris, S. M., Jr (1994) Coinduction of nitric oxide synthase and argininosuccinate synthetase in a murine macrophage cell line. Implications for regulation of nitric oxide production J. Biol. Chem. 269,1257-1261[Abstract/Free Full Text]
    285. 285
  285. Di Silvio, M., Geller, D. A., Gross, S. S., Nussler, A., Freeswick, P., Simmons, R. L., Billiar, T. R. (1993) Inducible nitric oxide synthase activity in hepatocytes is dependent on the coinduction of tetrahydrobiopterin synthesis Adv. Exp. Med. Biol. 338,305-308[Medline]
    286. 286
  286. Baek, K. J., Thiel, B. A., Lucas, S., Stuehr, D. J. (1993) Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme J. Biol. Chem. 268,21120-21129[Abstract/Free Full Text]
    287. 287
  287. Cassatella, M. A., Bazzoni, F., Flynn, R. M., Dusi, S., Trinchieri, G., Rossi, F. (1990) Molecular basis of interferon-gamma and lipopolysaccharide enhancement of phagocyte respiratory burst capability. Studies on the gene expression of several NADPH oxidase components J. Biol. Chem. 265,20241-20246[Abstract/Free Full Text]
    288. 288
  288. Newburger, P. E., Ezekowitz, R. A., Whitney, C., Wright, J., Orkin, S. H. (1988) Induction of phagocyte cytochrome b heavy chain gene expression by interferon gamma Proc. Natl. Acad. Sci. USA 85,5215-5219[Abstract/Free Full Text]
    289. 289
  289. Gupta, J. W., Kubin, M., Hartman, L., Cassatella, M., Trinchieri, G. (1992) Induction of expression of genes encoding components of the respiratory burst oxidase during differentiation of human myeloid cell lines induced by tumor necrosis factor and gamma-interferon Cancer Res. 52,2530-2537[Abstract/Free Full Text]
    290. 290
  290. Govoni, G., Vidal, S., Cellier, M., Lepage, P., Malo, D., Gros, P. (1995) Genomic structure, promoter sequence, and induction of expression of the mouse Nramp1 gene in macrophages Genomics 27,9-19[CrossRef][Medline]
    291. 291
  291. Erbe, D. V., Collins, J. E., Shen, L., Graziano, R. F., Fanger, M. W. (1990) The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells Mol. Immunol. 27,57-67[CrossRef][Medline]
    292. 292
  292. Strunk, R. C., Cole, F. S., Perlmutter, D. H., Colten, H. R. (1985) Gamma-interferon increases expression of class III complement genes C2 and factor B in human monocytes and in murine fibroblasts transfected with human C2 and factor B genes J. Biol. Chem. 260,15280-15285[Abstract/Free Full Text]
    293. 293
  293. Vincent, F., de la Salle, H., Bohbot, A., Bergerat, J. P., Hauptmann, G., Oberling, F. (1993) Synthesis and regulation of complement components by human monocytes/macrophages and by acute monocytic leukemia DNA Cell Biol. 12,415-423[Medline]
    294. 294
  294. Colten, H. R., Strunk, R. C., Perlmutter, D. H., Cole, F. S. (1986) Regulation of complement protein biosynthesis in mononuclear phagocytes Ciba Found. Symp. 118,141-154[Medline]
    295. 295
  295. Drevets, D. A., Leenen, P. J., Campbell, P. A. (1996) Complement receptor type 3 mediates phagocytosis and killing of Listeria monocytogenes by a TNF-alpha- and IFN-gamma-stimulated macrophage precursor hybrid Cell. Immunol. 169,1-6[CrossRef][Medline]
    296. 296
  296. Yoshida, A., Koide, Y., Uchijima, M., Yoshida, T. O. (1994) IFN-gamma induces IL-12 mRNA expression by a murine macrophage cell line, J774 Biochem. Biophys. Res. Commun. 198,857-861[CrossRef][Medline]
    297. 297
  297. Kubin, M., Chow, J. M., Trinchieri, G. (1994) Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells Blood 83,1847-1855[Abstract/Free Full Text]
    298. 298
  298. Taub, D. D., Lloyd, A. R., Conlon, K., Wang, J. M., Ortaldo, J. R., Harada, A., Matsushima, K., Kelvin, D. J., Oppenheim, J. J. (1993) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells J. Exp. Med. 177,1809-1814[Abstract/Free Full Text]
    299. 299
  299. Rollins, B. J., Yoshimura, T., Leonard, E. J., Pober, J. S. (1990) Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE Am. J. Pathol. 136,1229-1233[Abstract]
    300. 300
  300. Liao, F., Rabin, R. L., Yannelli, J. R., Koniaris, L. G., Vanguri, P., Farber, J. M. (1995) Human Mig chemokine: biochemical and functional characterization J. Exp. Med. 182,1301-1314[Abstract/Free Full Text]
    301. 301
  301. Taub, D. D., Conlon, K., Lloyd, A. R., Oppenheim, J. J., Kelvin, D. J. (1993) Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta Science 260,355-358[Abstract/Free Full Text]
    302. 302
  302. Appay, V., Rowland-Jones, S. L. (2001) RANTES: a versatile and controversial chemokine Trends Immunol. 22,83-87[CrossRef][Medline]
    303. 303
  303. Hou, J., Baichwal, V., Cao, Z. (1994) Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1 Proc. Natl. Acad. Sci. USA 91,11641-11645[Abstract/Free Full Text]
    304. 304
  304. Jesse, T. L., LaChance, R., Iademarco, M. F., Dean, D. C. (1998) Interferon regulatory factor-2 is a transcriptional activator in muscle where it regulates expression of vascular cell adhesion molecule-1 J. Cell Biol. 140,1265-1276[Abstract/Free Full Text]
    305. 305
  305. Billiau, A. (1996) Interferon-gamma: biology and role in pathogenesis Adv. Immunol. 62,61-130[Medline]
    306. 307
  306. York, I. A., Rock, K. L. (1996) Antigen processing and presentation by the class I major histocompatibility complex Annu. Rev. Immunol. 14,369-396[CrossRef][Medline]
    307. 308
  307. Grandea, A. G., III, Androlewicz, M. J., Athwal, R. S., Geraghty, D. E., Spies, T. (1995) Dependence of peptide binding by MHC class I molecules on their interaction with TAP Science 270,105-108[Abstract/Free Full Text]
    308. 309
  308. Anderson, S. L., Shen, T., Lou, J., Xing, L., Blachere, N. E., Srivastava, P. K., Rubin, B. Y. (1994) The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells J. Exp. Med. 180,1565-1569[Abstract/Free Full Text]
    309. 310
  309. Suto, R., Srivastava, P. K. (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides Science 269,1585-1588[Abstract/Free Full Text]
    310. 311
  310. Chang, C. H., Guerder, S., Hong, S. C., van Ewijk, W., Flavell, R. A. (1996) Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression Immunity 4,167-178[CrossRef][Medline]
    311. 312
  311. Griscelli, C., Lisowska-Grospierre, B., Mach, B. (1989) Combined immunodeficiency with defective expression in MHC class II genes Immunodefic. Rev. 1,135-153[Medline]
    312. 313
  312. Chang, C. H., Fontes, J. D., Peterlin, M., Flavell, R. A. (1994) Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes J. Exp. Med. 180,1367-1374[Abstract/Free Full Text]
    313. 314
  313. Waldburger, J. M., Masternak, K., Muhlethaler-Mottet, A., Villard, J., Peretti, M., Landmann, S., Reith, W. (2000) Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression Immunol. Rev. 178,148-165[CrossRef][Medline]
    314. 315
  314. Boss, J. M. (1997) Regulation of transcription of MHC class II genes Curr. Opin. Immunol. 9,107-113[CrossRef][Medline]
    315. 316
  315. Heufler, C., Koch, F., Stanzl, U., Topar, G., Wysocka, M., Trinchieri, G., Enk, A., Steinman, R. M., Romani, N., Schuler, G. (1996) Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells Eur. J. Immunol. 26,659-668[Medline]
    316. 317
  316. Coutelier, J. P., Van Broeck, J., Wolf, S. F. (1995) Interleukin-12 gene expression after viral infection in the mouse J. Virol. 69,1955-1958[Abstract]
    317. 318
  317. Bliss, S. K., Marshall, A. J., Zhang, Y., Denkers, E. Y. (1999) Human polymorphonuclear leukocytes produce IL-12, TNF-alpha, and the chemokines macrophage-inflammatory protein-1 alpha and -1 beta in response to Toxoplasma gondii antigens J. Immunol. 162,7369-7375[Abstract/Free Full Text]
    318. 319
  318. Cassatella, M. A., Meda, L., Gasperini, S., D’Andrea, A., Ma, X., Trinchieri, G. (1995) Interleukin-12 production by human polymorphonuclear leukocytes Eur. J. Immunol. 25,1-5[Medline]
    319. 320
  319. Macatonia, S. E., Hosken, N. A., Litton, M., Vieira, P., Hsieh, C. S., Culpepper, J. A., Wysocka, M., Trinchieri, G., Murphy, K. M., O’Garra, A. (1995) Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells J. Immunol. 154,5071-5079[Abstract]
    320. 321
  320. Lederer, J. A., Perez, V. L., DesRoches, L., Kim, S. M., Abbas, A. K., Lichtman, A. H. (1996) Cytokine transcriptional events during helper T cell subset differentiation J. Exp. Med. 184,397-406[Abstract/Free Full Text]
    321. 322
  321. Trinchieri, G. (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity Annu. Rev. Immunol. 13,251-276[Medline]
    322. 323
  322. Morinobu, A., Kumagai, S. (1998) Cytokine measurement at a single-cell level to analyze human Th1 and Th2 cells Rinsho Byori 46,908-914[Medline]
    323. 324
  323. Lehn, M., Weiser, W. Y., Engelhorn, S., Gillis, S., Remold, H. G. (1989) IL-4 inhibits H2O2 production and antileishmanial capacity of human cultured monocytes mediated by IFN-gamma J. Immunol. 143,3020-3024[Abstract]
    324. 325
  324. Liew, F. Y., Li, Y., Severn, A., Millott, S., Schmidt, J., Salter, M., Moncada, S. (1991) A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages Eur. J. Immunol. 21,2489-2494[Medline]
    325. 326
  325. Rousset, F., Malefijt, R. W., Slierendregt, B., Aubry, J. P., Bonnefoy, J. Y., Defrance, T., Banchereau, J., de Vries, J. E. (1988) Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt’s lymphoma cell lines by human IL-4 and IFN-gamma J. Immunol. 140,2625-2632[Abstract]
    326. 327
  326. Taniguchi, T., Takaoka, A. (2002) The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors Curr. Opin. Immunol. 14,111-116[CrossRef][Medline]
    327. 328
  327. Lu, B., Ebensperger, C., Dembic, Z., Wang, Y., Kvatyuk, M., Lu, T., Coffman, R. L., Pestka, S., Rothman, P. B. (1998) Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice Proc. Natl. Acad. Sci. USA 95,8233-8238[Abstract/Free Full Text]
    328. 329
  328. Cantin, E., Tanamachi, B., Openshaw, H. (1999) Role for gamma interferon in control of herpes simplex virus type 1 reactivation J. Virol. 73,3418-3423[Abstract/Free Full Text]
    329. 330
  329. Beretta, L., Gabbay, M., Berger, R., Hanash, S. M., Sonenberg, N. (1996) Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q-associated leukemias Oncogene 12,1593-1596[Medline]
    330. 331
  330. Hovanessian, A. G., Galabru, J. (1987) The double-stranded RNA-dependent protein kinase is also activated by heparin Eur. J. Biochem. 167,467-473[Medline]
    331. 332
  331. Goodbourn, S., Didcock, L., Randall, R. E. (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures J. Gen. Virol. 81,2341-2364[Free Full Text]
    332. 333
  332. Lee, S. B., Melkova, Z., Yan, W., Williams, B. R., Hovanessian, A. G., Esteban, M. (1993) The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells Virology 192,380-385[CrossRef][Medline]
    333. 334
  333. Chu, W. M., Ostertag, D., Li, Z. W., Chang, L., Chen, Y., Hu, Y., Williams, B., Perrault, J., Karin, M. (1999) JNK2 and IKKbeta are required for activating the innate response to viral infection Immunity 11,721-731[CrossRef][Medline]
    334. 335
  334. Zhou, A., Paranjape, J. M., Der, S. D., Williams, B. R., Silverman, R. H. (1999) Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways Virology 258,435-440[CrossRef][Medline]
    335. 336
  335. Presti, R. M., Popkin, D. L., Connick, M., Paetzold, S., Virgin, H. W., IV (2001) Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages J. Exp. Med. 193,483-496[Abstract/Free Full Text]
    336. 337
  336. Xaus, J., Comalada, M., Valledor, A. F., Cardo, M., Herrero, C., Soler, C., Lloberas, J., Celada, A. (2001) Molecular mechanisms involved in macrophage survival, proliferation, activation or apoptosis Immunobiology 204,543-550[CrossRef][Medline]
    337. 338
  337. Breen, F. N., Hume, D. A., Weidemann, M. J. (1991) Interactions among granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IFN-gamma lead to enhanced proliferation of murine macrophage progenitor cells J. Immunol. 147,1542-1547[Abstract]
    338. 339
  338. Balkwill, F., Taylor-Papadimitriou, J. (1978) Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth Nature 274,798-800[CrossRef][Medline]
    339. 340
  339. Roos, G., Leanderson, T., Lundgren, E. (1984) Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells Cancer Res. 44,2358-2362[Abstract/Free Full Text]
    340. 341
  340. Lundblad, D., Lundgren, E. (1981) Block of glioma cell line in S by interferon Int. J. Cancer 27,749-754[Medline]
    341. 342
  341. Tiefenbrun, N., Melamed, D., Levy, N., Resnitzky, D., Hoffman, I., Reed, S. I., Kimchi, A. (1996) Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest Mol. Cell. Biol. 16,3934-3944[Abstract]
    342. 343
  342. Sangfelt, O., Erickson, S., Einhorn, S., Grander, D. (1997) Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines Oncogene 14,415-423[CrossRef][Medline]
    343. 344
  343. Hobeika, A. C., Subramaniam, P. S., Johnson, H. M. (1997) IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells Oncogene 14,1165-1170[CrossRef][Medline]
    344. 345
  344. Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y., Fu, X. Y. (1996) Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1 Science 272,719-722[Abstract]
    345. 346
  345. Takami, K., Takuwa, N., Okazaki, H., Kobayashi, M., Ohtoshi, T., Kawasaki, S., Dohi, M., Yamamoto, K., Nakamura, T., Tanaka, M., Nakahara, K., Takuwa, Y., Takizawa, H. (2002) Interferon-gamma inhibits hepatocyte growth factor-stimulated cell proliferation of human bronchial epithelial cells: upregulation of p27(kip1) cyclin-dependent kinase inhibitor Am. J. Respir. Cell Mol. Biol. 26,231-238[Abstract/Free Full Text]
    346. 347
  346. Dey, A., Kim, L., Li, W. (1999) Gamma interferon induces expression of Mad1 gene in macrophage, which inhibits colony-stimulating factor-1-dependent mitogenesis J. Cell. Biochem. 72,232-241[CrossRef][Medline]
    347. 348
  347. Thornberry, N. A. (1998) Caspases: key mediators of apoptosis Chem. Biol. 5,R97-R103[CrossRef][Medline]
    348. 349
  348. Novelli, F., Bernabei, P., Ozmen, L., Rigamonti, L., Allione, A., Pestka, S., Garotta, G., Forni, G. (1996) Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor J. Immunol. 157,1935-1943[Abstract]
    349. 350
  349. Bernabei, P., Allione, A., Rigamonti, L., Bosticardo, M., Losana, G., Borghi, I., Forni, G., Novelli, F. (2001) Regulation of interferon-gamma receptor (INF-gammaR) chains: a peculiar way to rule the life and death of human lymphocytes Eur. Cytokine Netw. 12,6-14[Medline]
    350. 351
  350. Los, M., Van de Craen, M., Penning, L. C., Schenk, H., Westendorp, M., Baeuerle, P. A., Droge, W., Krammer, P. H., Fiers, W., Schulze-Osthoff, K. (1995) Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis Nature 375,81-83[CrossRef][Medline]
    351. 352
  351. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A., Yuan, J. (1993) Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 Cell 75,653-660[CrossRef][Medline]
    352. 353
  352. Mathiak, G., Grass, G., Herzmann, T., Luebke, T., Zetina, C. C., Boehm, S. A., Bohlen, H., Neville, L. F., Hoelscher, A. H. (2000) Caspase-1-inhibitor ac-YVAD-cmk reduces LPS-lethality in rats without affecting haematology or cytokine responses Br. J. Pharmacol. 131,383-386[CrossRef][Medline]
    353. 354
  353. Fantuzzi, G., Dinarello, C. A. (1999) Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1) J. Clin. Immunol. 19,1-11[CrossRef][Medline]
    354. 355
  354. Roos, D., Bolscher, B. G. J., de Boer, M. (1992) Generation of reactive oxygen species by phagocytes van Furth, R. eds. Mononuclear Phagocytes: Biology of Monocytes and Macrophages ,243-253 Kluwer Academic Dordrecht, The Netherlands.
    355. 356
  355. Nathan, C. F., Gabay, J. (1992) Antimicrobial mechanisms of macrophages van Furth, R. eds. Mononuclear Phagocytes: Biology of Monocytes and Macrophages ,259-267 Kluwer Academic Dordrecht, The Netherlands.
    356. 357
  356. Shiloh, M. U., MacMicking, J. D., Nicholson, S., Brause, J. E., Potter, S., Marino, M., Fang, F., Dinauer, M., Nathan, C. (1999) Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase Immunity 10,29-38[CrossRef][Medline]
    357. 358
  357. Karupiah, G., Xie, Q. W., Buller, R. M., Nathan, C., Duarte, C., MacMicking, J. D. (1993) Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase Science 261,1445-1448[Abstract/Free Full Text]
    358. 359
  358. Green, S. J., Nacy, C. A., Meltzer, M. S. (1991) Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens J. Leukoc. Biol. 50,93-103[Medline]
    359. 360
  359. Green, S. J., Crawford, R. M., Hockmeyer, J. T., Meltzer, M. S., Nacy, C. A. (1990) Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha J. Immunol. 145,4290-4297[Abstract]
    360. 361
  360. Denis, M. (1991) Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates J. Leukoc. Biol. 49,380-387[Abstract]
    361. 362
  361. Wei, X. Q., Charles, I. G., Smith, A., Ure, J., Feng, G. J., Huang, F. P., Xu, D., Muller, W., Moncada, S., Liew, F. Y. (1995) Altered immune responses in mice lacking inducible nitric oxide synthase Nature 375,408-411[CrossRef][Medline]
    362. 363
  362. Karupiah, G., Chen, J. H., Nathan, C. F., Mahalingam, S., MacMicking, J. D. (1998) Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection J. Virol. 72,7703-7706[Abstract/Free Full Text]
    363. 364
  363. Guidotti, L. G., McClary, H., Loudis, J. M., Chisari, F. V. (2000) Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice J. Exp. Med. 191,1247-1252[Abstract/Free Full Text]
    364. 365
  364. Kwon, N. S., Nathan, C. F., Stuehr, D. J. (1989) Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages J. Biol. Chem. 264,20496-20501[Abstract/Free Full Text]
    365. 366
  365. Drapier, J. C., Wietzerbin, J., Hibbs, J. B., Jr (1988) Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages Eur. J. Immunol. 18,1587-1592[Medline]
    366. 367
  366. Morris, S. M., Jr, Billiar, T. R. (1994) New insights into the regulation of inducible nitric oxide synthesis Am. J. Physiol. 266,E829-E839
    367. 368
  367. Kamijo, R., Shapiro, D., Le, J., Huang, S., Aguet, M., Vilcek, J. (1993) Generation of nitric oxide and induction of major histocompatibility complex class II antigen in macrophages from mice lacking the interferon gamma receptor Proc. Natl. Acad. Sci. USA 90,6626-6630[Abstract/Free Full Text]
    368. 369
  368. Kamijo, R., Harada, H., Matsuyama, T., Bosland, M., Gerecitano, J., Shapiro, D., Le, J., Koh, S. I., Kimura, T., Green, S. J., et al (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages Science 263,1612-1615[Abstract/Free Full Text]
    369. 370
  369. Radi, R., Beckman, J. S., Bush, K. M., Freeman, B. A. (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide Arch. Biochem. Biophys. 288,481-487[CrossRef][Medline]
    370. 371
  370. Radi, R., Beckman, J. S., Bush, K. M., Freeman, B. A. (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide J. Biol. Chem. 266,4244-4250[Abstract/Free Full Text]
    371. 372
  371. Cassatella, M. A., Hartman, L., Perussia, B., Trinchieri, G. (1989) Tumor necrosis factor and immune interferon synergistically induce cytochrome b-245 heavy-chain gene expression and nicotinamide-adenine dinucleotide phosphate hydrogenase oxidase in human leukemic myeloid cells J. Clin. Invest. 83,1570-1579
    372. 373
  372. Pfefferkorn, E. R. (1984) Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan Proc. Natl. Acad. Sci. USA 81,908-912[Abstract/Free Full Text]
    373. 374
  373. Burke, F., Knowles, R. G., East, N., Balkwill, F. R. (1995) The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo Int. J. Cancer 60,115-122[Medline]
    374. 375
  374. Hissong, B. D., Carlin, J. M. (1997) Potentiation of interferon-induced indoleamine 2,3-dioxygenase mRNA in human mononuclear phagocytes by lipopolysaccharide and interleukin-1 J. Interferon Cytokine Res. 17,387-393[Medline]
    375. 376
  375. Carlin, J. M., Borden, E. C., Sondel, P. M., Byrne, G. I. (1987) Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures J. Immunol. 139,2414-2418[Abstract]
    376. 377
  376. Hassanain, H. H., Chon, S. Y., Gupta, S. L. (1993) Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-gamma and -alpha. Analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor J. Biol. Chem. 268,5077-5084[Abstract/Free Full Text]
    377. 378
  377. Fleckner, J., Martensen, P. M., Tolstrup, A. B., Kjeldgaard, N. O., Justesen, J. (1995) Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines Cytokine 7,70-77[CrossRef][Medline]
    378. 379
  378. Kisselev, L., Frolova, L., Haenni, A. L. (1993) Interferon inducibility of mammalian tryptophanyl-tRNA synthetase: new perspectives Trends Biochem. Sci. 18,263-267[CrossRef][Medline]
    379. 380
  379. Xue, H., Wong, J. T. (1995) Interferon induction of human tryptophanyl-tRNA synthetase safeguards the synthesis of tryptophan-rich immune-system proteins: a hypothesis Gene 165,335-339[CrossRef][Medline]
    380. 381
  380. Collins, J. T., Dunnick, W. A. (1993) Germline transcripts of the murine immunoglobulin gamma 2a gene: structure and induction by IFN-gamma Int. Immunol. 5,885-891[Abstract/Free Full Text]
    381. 382
  381. Snapper, C. M., Paul, W. E. (1987) Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production Science 236,944-947[Abstract/Free Full Text]
    382. 383
  382. Sweet, M. J., Hume, D. A. (1996) Endotoxin signal transduction in macrophages J. Leukoc. Biol. 60,8-26[Abstract]
    383. 384
  383. Akira, S. (2000) Toll-like receptors: lessons from knockout mice Biochem. Soc. Trans. 28,551-556[Medline]
    384. 385
  384. Aderem, A., Ulevitch, R. J. (2000) Toll-like receptors in the induction of the innate immune response Nature 406,782-787[CrossRef][Medline]
    385. 386
  385. Dobrovolskaia, M. A., Vogel, S. N. (2002) Toll receptors, CD14, and macrophage activation and deactivation by LPS Microbes Infect. 4,903-914[CrossRef][Medline]
    386. 387
  386. Kawai, T., Adachi, O., Ogawa, T., Takeda, K., Akira, S. (1999) Unresponsiveness of MyD88-deficient mice to endotoxin Immunity 11,115-122[CrossRef][Medline]
    387. 388
  387. Lorsbach, R. B., Murphy, W. J., Lowenstein, C. J., Snyder, S. H., Russell, S. W. (1993) Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide J. Biol. Chem. 268,1908-1913[Abstract/Free Full Text]
    388. 389
  388. Jurkovich, G. J., Mileski, W. J., Maier, R. V., Winn, R. K., Rice, C. L. (1991) Interferon gamma increases sensitivity to endotoxin J. Surg. Res. 51,197-203[CrossRef][Medline]
    389. 390
  389. Sweet, M. J., Stacey, K. J., Kakuda, D. K., Markovich, D., Hume, D. A. (1998) IFN-gamma primes macrophage responses to bacterial DNA J. Interferon Cytokine Res. 18,263-271[Medline]
    390. 391
  390. Vadiveloo, P. K., Vairo, G., Hertzog, P., Kola, I., Hamilton, J. A. (2000) Role of type I interferons during macrophage activation by lipopolysaccharide Cytokine 12,1639-1646[CrossRef][Medline]
    391. 392
  391. Costelloe, E. A. (1997) The regulation and function of murine PAI-2 Centre for Molecular and Cellular Biology ,158 Biochemistry Department, University of Queensland Brisbane, Australia.
    392. 393
  392. Williams, J. G., Jurkovich, G. J., Hahnel, G. B., Maier, R. V. (1992) Macrophage priming by interferon gamma: a selective process with potentially harmful effects J. Leukoc. Biol. 52,579-584[Abstract]
    393. 394
  393. Car, B. D., Eng, V. M., Schnyder, B., Ozmen, L., Huang, S., Gallay, P., Heumann, D., Aguet, M., Ryffel, B. (1994) Interferon gamma receptor deficient mice are resistant to endotoxic shock J. Exp. Med. 179,1437-1444[Abstract/Free Full Text]
    394. 395
  394. Bosisio, D., Polentarutti, N., Sironi, M., Bernasconi, S., Miyake, K., Webb, G. R., Martin, M. U., Mantovani, A., Muzio, M. (2002) Stimulation of Toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide Blood 99,3427-3431[Abstract/Free Full Text]
    395. 396
  395. Mita, Y., Dobashi, K., Shimizu, Y., Nakazawa, T., Mori, M. (2001) Toll-like receptor 2 and 4 surface expressions on human monocytes are modulated by interferon-gamma and macrophage colony-stimulating factor Immunol. Lett. 78,97-101[CrossRef][Medline]
    396. 397
  396. Darmani, H., Parton, J., Harwood, J. L., Jackson, S. K. (1994) Interferon-gamma and polyunsaturated fatty acids increase the binding of lipopolysaccharide to macrophages Int. J. Exp. Pathol. 75,363-368[Medline]
    397. 398
  397. Adib-Conquy, M., Cavaillon, J. M. (2002) Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression J. Biol. Chem. 277,27927-27934[Abstract/Free Full Text]
    398. 399
  398. Held, T. K., Weihua, X., Yuan, L., Kalvakolanu, D. V., Cross, A. S. (1999) Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1 Infect. Immun. 67,206-212[Abstract/Free Full Text]
    399. 400
  399. de Wit, H., Hoogstraten, D., Halie, R. M., Vellenga, E. (1996) Interferon-gamma modulates the lipopolysaccharide-induced expression of AP-1 and NF-kappa B at the mRNA and protein level in human monocytes Exp. Hematol. 24,228-235[Medline]
    400. 401
  400. Huang, Y., Krein, P. M., Muruve, D. A., Winston, B. W. (2002) Complement factor B gene regulation: synergistic effects of TNF-alpha and IFN-gamma in macrophages J. Immunol. 169,2627-2635[Abstract/Free Full Text]
    401. 402
  401. Jahnke, A., Johnson, J. P. (1994) Synergistic activation of intercellular adhesion molecule 1 (ICAM-1) by TNF-alpha and IFN-gamma is mediated by p65/p50 and p65/c-Rel and interferon-responsive factor Stat1 alpha (p91) that can be activated by both IFN-gamma and IFN-alpha FEBS Lett. 354,220-226[CrossRef][Medline]
    402. 403
  402. Cheshire, J. L., Baldwin, A. S., Jr (1997) Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaB beta degradation Mol. Cell. Biol. 17,6746-6754[Abstract]
    403. 404
  403. Ohmori, Y., Schreiber, R. D., Hamilton, T. A. (1997) Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB J. Biol. Chem. 272,14899-14907[Abstract/Free Full Text]
    404. 405
  404. Fujita, T., Reis, L. F., Watanabe, N., Kimura, Y., Taniguchi, T., Vilcek, J. (1989) Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways Proc. Natl. Acad. Sci. USA 86,9936-9940[Abstract/Free Full Text]
    405. 406
  405. Han, Y., Rogers, N., Ransohoff, R. M. (1999) Tumor necrosis factor-alpha signals to the IFN-gamma receptor complex to increase Stat1alpha activation J. Interferon Cytokine Res. 19,731-740[CrossRef][Medline]
    406. 407
  406. Kumar, A., Haque, J., Lacoste, J., Hiscott, J., Williams, B. R. (1994) Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B Proc. Natl. Acad. Sci. USA 91,6288-6292[Abstract/Free Full Text]
    407. 408
  407. Tannenbaum, C. S., Major, J. A., Hamilton, T. A. (1993) IFN-gamma and lipopolysaccharide differentially modulate expression of tumor necrosis factor receptor mRNA in murine peritoneal macrophages J. Immunol. 151,6833-6839[Abstract]
    408. 409
  408. Aggarwal, B. B., Eessalu, T. E., Hass, P. E. (1985) Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon Nature 318,665-667[CrossRef][Medline]
    409. 410
  409. Michishita, M., Yoshida, Y., Uchino, H., Nagata, K. (1990) Induction of tumor necrosis factor-alpha and its receptors during differentiation in myeloid leukemic cells along the monocytic pathway. A possible regulatory mechanism for TNF-alpha production J. Biol. Chem. 265,8751-8759[Abstract/Free Full Text]
    410. 411
  410. Aggarwal, B. B., Eessalu, T. E. (1987) Induction of receptors for tumor necrosis factor-alpha by interferons is not a major mechanism for their synergistic cytotoxic response J. Biol. Chem. 262,10000-10007[Abstract/Free Full Text]
    411. 412
  411. Rhee, S. H., Jones, B. W., Toshchakov, V., Vogel, S. N., Fenton, M. J. (2003) Toll-like receptor 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages J. Biol. Chem. 278,22506-22512[Abstract/Free Full Text]
    412. 413
  412. Gao, J. J., Filla, M. B., Fultz, M. J., Vogel, S. N., Russell, S. W., Murphy, W. J. (1998) Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene J. Immunol. 161,4803-4810[Abstract/Free Full Text]
    413. 414
  413. Gessani, S., Belardelli, F., Pecorelli, A., Puddu, P., Baglioni, C. (1989) Bacterial lipopolysaccharide and gamma interferon induce transcription of beta interferon mRNA and interferon secretion in murine macrophages J. Virol. 63,2785-2789[Abstract/Free Full Text]
    414. 415
  414. Toshchakov, V., Jones, B. W., Perera, P. Y., Thomas, K., Cody, M. J., Zhang, S., Williams, B. R., Major, J., Hamilton, T. A., Fenton, M. J., Vogel, S. N. (2002) TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages Nat. Immunol. 3,392-398[CrossRef][Medline]
    415. 416
  415. Ohmori, Y., Hamilton, T. A. (2001) Requirement for STAT1 in LPS-induced gene expression in macrophages J. Leukoc. Biol. 69,598-604[Abstract/Free Full Text]
    416. 417
  416. Kawai, T., Takeuchi, O., Fujita, T., Inoue, J., Muhlradt, P. F., Sato, S., Hoshino, K., Akira, S. (2001) Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes J. Immunol. 167,5887-5894[Abstract/Free Full Text]
    417. 418
  417. Ohmori, Y., Hamilton, T. A. (1995) The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha J. Immunol. 154,5235-5244[Abstract]
    418. 419
  418. Gao, J., Morrison, D. C., Parmely, T. J., Russell, S. W., Murphy, W. J. (1997) An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide J. Biol. Chem. 272,1226-1230[Abstract/Free Full Text]
    419. 420
  419. Xie, Q. W., Kashiwabara, Y., Nathan, C. (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase J. Biol. Chem. 269,4705-4708[Abstract/Free Full Text]
    420. 421
  420. Ledebur, H. C., Parks, T. P. (1995) Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers J. Biol. Chem. 270,933-943[Abstract/Free Full Text]
    421. 422
  421. Caldenhoven, E., Coffer, P., Yuan, J., Van de Stolpe, A., Horn, F., Kruijer, W., Van der Saag, P. T. (1994) Stimulation of the human intercellular adhesion molecule-1 promoter by interleukin-6 and interferon-gamma involves binding of distinct factors to a palindromic response element J. Biol. Chem. 269,21146-21154[Abstract/Free Full Text]
    422. 423
  422. Look, D. C., Pelletier, M. R., Holtzman, M. J. (1994) Selective interaction of a subset of interferon-gamma response element-binding proteins with the intercellular adhesion molecule-1 (ICAM-1) gene promoter controls the pattern of expression on epithelial cells J. Biol. Chem. 269,8952-8958[Abstract/Free Full Text]
    423. 424
  423. Hume, D. A. (2000) Probability in transcriptional regulation and its implications for leukocyte differentiation and inducible gene expression Blood 96,2323-2328[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
X. S. Liu, J. Leerberg, K. MacDonald, G. R. Leggatt, and I. H. Frazer
IFN-{gamma} Promotes Generation of IL-10 Secreting CD4+ T Cells that Suppress Generation of CD8 Responses in an Antigen-Experienced Host
J. Immunol., July 1, 2009; 183(1): 51 - 58.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. M. Cathcart, M. A. Fields, M. Zheng, B. Marshall, and S. S. Atherton
Infiltrating Cells and IFN{gamma} Production in the Injected Eye after Uniocular Anterior Chamber Inoculation of HSV-1
Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2269 - 2275.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Malur, A. J. Mccoy, S. Arce, B. P. Barna, M. S. Kavuru, A. G. Malur, and M. J. Thomassen
Deletion of PPAR{gamma} in Alveolar Macrophages Is Associated with a Th-1 Pulmonary Inflammatory Response
J. Immunol., May 1, 2009; 182(9): 5816 - 5822.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. L. Ogilvie, J. R. SternJohn, B. Rattenbacher, I. A. Vlasova, D. A. Williams, H. H. Hau, P. J. Blackshear, and P. R. Bohjanen
Tristetraprolin Mediates Interferon-{gamma} mRNA Decay
J. Biol. Chem., April 24, 2009; 284(17): 11216 - 11223.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. J. Park, M. A. Hughes, M. Burdick, R. M. Strieter, and B. Mehrad
Early NK Cell-Derived IFN-{gamma} Is Essential to Host Defense in Neutropenic Invasive Aspergillosis
J. Immunol., April 1, 2009; 182(7): 4306 - 4312.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
D. D. Bannerman
Pathogen-dependent induction of cytokines and other soluble inflammatory mediators during intramammary infection of dairy cows
J Anim Sci, April 1, 2009; 87(13_suppl): 10 - 25.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Lopez-Munoz, F. J. Roca, J. Meseguer, and V. Mulero
New Insights into the Evolution of IFNs: Zebrafish Group II IFNs Induce a Rapid and Transient Expression of IFN-Dependent Genes and Display Powerful Antiviral Activities
J. Immunol., March 15, 2009; 182(6): 3440 - 3449.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. M. Olson Jr., T. C. Bates, H. Izadi, J. D. Radolf, S. A. Huber, J. E. Boyson, and J. Anguita
Local Production of IFN-{gamma} by Invariant NKT Cells Modulates Acute Lyme Carditis
J. Immunol., March 15, 2009; 182(6): 3728 - 3734.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Li, M. VanRoey, C. Wang, T.-h. T. Chen, A. Korman, and K. Jooss
Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
Clin. Cancer Res., March 1, 2009; 15(5): 1623 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Sattler, U. Wagner, M. Rossol, J. Sieper, P. Wu, A. Krause, W. A. Schmidt, S. Radmer, S. Kohler, C. Romagnani, et al.
Cytokine-induced human IFN-{gamma}-secreting effector-memory Th cells in chronic autoimmune inflammation
Blood, February 26, 2009; 113(9): 1948 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
W. Yang, H. Li, P. W. Chen, H. Alizadeh, Y. He, R. N. Hogan, and J. Y. Niederkorn
PD-L1 Expression on Human Ocular Cells and Its Possible Role in Regulating Immune-Mediated Ocular Inflammation
Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 273 - 280.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
D. S. Gridley, J. M. Slater, X. Luo-Owen, A. Rizvi, S. K. Chapes, L. S. Stodieck, V. L. Ferguson, and M. J. Pecaut
Spaceflight effects on T lymphocyte distribution, function and gene expression
J Appl Physiol, January 1, 2009; 106(1): 194 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
K. Nakamura, Y. Komagiri, T. Kojo, and M. Kubokawa
Delayed and acute effects of interferon-{gamma} on activity of an inwardly rectifying K+ channel in cultured human proximal tubule cells
Am J Physiol Renal Physiol, January 1, 2009; 296(1): F46 - F53.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Negishi, T. Osawa, K. Ogami, X. Ouyang, S. Sakaguchi, R. Koshiba, H. Yanai, Y. Seko, H. Shitara, K. Bishop, et al.
A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity
PNAS, December 23, 2008; 105(51): 20446 - 20451.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. C. Miller, Y. Ma, J. Bian, K. C. F. Sheehan, J. F. Zachary, J. H. Weis, R. D. Schreiber, and J. J. Weis
A Critical Role for Type I IFN in Arthritis Development following Borrelia burgdorferi Infection of Mice
J. Immunol., December 15, 2008; 181(12): 8492 - 8503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Shi, M. Sakuma, T. Mooroka, A. Liscoe, H. Gao, K. J. Croce, A. Sharma, D. Kaplan, D. R. Greaves, Y. Wang, et al.
Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function
Blood, December 1, 2008; 112(12): 4699 - 4711.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. A. Hume
Macrophages as APC and the Dendritic Cell Myth
J. Immunol., November 1, 2008; 181(9): 5829 - 5835.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
A. De Lerma Barbaro, A. De Ambrosis, B. Banelli, G. L. Pira, O. Aresu, M. Romani, S. Ferrini, and R. S. Accolla
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-{gamma} in promyelocytic cells
Int. Immunol., November 1, 2008; 20(11): 1457 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Baron and J.-L. Davignon
Inhibition of IFN-{gamma}-Induced STAT1 Tyrosine Phosphorylation by Human CMV Is Mediated by SHP2
J. Immunol., October 15, 2008; 181(8): 5530 - 5536.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. Wu and S. N. Meydani
Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention
J. Leukoc. Biol., October 1, 2008; 84(4): 900 - 914.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
R. De Pascalis, B. C. Taylor, and K. L. Elkins
Diverse Myeloid and Lymphoid Cell Subpopulations Produce Gamma Interferon during Early Innate Immune Responses to Francisella tularensis Live Vaccine Strain
Infect. Immun., September 1, 2008; 76(9): 4311 - 4321.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
C. Cosseau, D. A. Devine, E. Dullaghan, J. L. Gardy, A. Chikatamarla, S. Gellatly, L. L. Yu, J. Pistolic, R. Falsafi, J. Tagg, et al.
The Commensal Streptococcus salivarius K12 Downregulates the Innate Immune Responses of Human Epithelial Cells and Promotes Host-Microbe Homeostasis
Infect. Immun., September 1, 2008; 76(9): 4163 - 4175.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J.-S. Delisle, L. Gaboury, M.-P. Belanger, E. Tasse, H. Yagita, and C. Perreault
Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-{gamma} receptor-deficient hosts
Blood, September 1, 2008; 112(5): 2111 - 2119.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. B. Wilson, M. Ray, M. Lutz, D. Sharda, J. Xu, and P. A. Hankey
The RON Receptor Tyrosine Kinase Regulates IFN-{gamma} Production and Responses in Innate Immunity
J. Immunol., August 15, 2008; 181(4): 2303 - 2310.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. J. Opiela, R. B. Levy, and B. Adkins
Murine neonates develop vigorous in vivo cytotoxic and Th1/Th2 responses upon exposure to low doses of NIMA-like alloantigens
Blood, August 15, 2008; 112(4): 1530 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Beurel and R. S. Jope
Differential Regulation of STAT Family Members by Glycogen Synthase Kinase-3
J. Biol. Chem., August 8, 2008; 283(32): 21934 - 21944.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
V. V. Kravchenko, G. F. Kaufmann, J. C. Mathison, D. A. Scott, A. Z. Katz, D. C. Grauer, M. Lehmann, M. M. Meijler, K. D. Janda, and R. J. Ulevitch
Modulation of Gene Expression via Disruption of NF-{kappa}B Signaling by a Bacterial Small Molecule
Science, July 11, 2008; 321(5886): 259 - 263.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
U. Kintscher, M. Hartge, K. Hess, A. Foryst-Ludwig, M. Clemenz, M. Wabitsch, P. Fischer-Posovszky, T. F.E. Barth, D. Dragun, T. Skurk, et al.
T-lymphocyte Infiltration in Visceral Adipose Tissue: A Primary Event in Adipose Tissue Inflammation and the Development of Obesity-Mediated Insulin Resistance
Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1304 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Strowig, F. Brilot, and C. Munz
Noncytotoxic Functions of NK Cells: Direct Pathogen Restriction and Assistance to Adaptive Immunity
J. Immunol., June 15, 2008; 180(12): 7785 - 7791.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Hu, X. Hu, L. Boumsell, and L. B. Ivashkiv
IFN-{gamma} and STAT1 Arrest Monocyte Migration and Modulate RAC/CDC42 Pathways
J. Immunol., June 15, 2008; 180(12): 8057 - 8065.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Sexton and A. C. Harrison
Susceptibility to nontuberculous mycobacterial lung disease
Eur. Respir. J., June 1, 2008; 31(6): 1322 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. C. Rupper and J. A. Cardelli
Induction of Guanylate Binding Protein 5 by Gamma Interferon Increases Susceptibility to Salmonella enterica Serovar Typhimurium-Induced Pyroptosis in RAW 264.7 Cells
Infect. Immun., June 1, 2008; 76(6): 2304 - 2315.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. D. Shao, R. Suresh, V. Vakil, R. H. Gomer, and D. Pilling
Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation
J. Leukoc. Biol., June 1, 2008; 83(6): 1323 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Lembo, M. Pelletier, R. Iyer, M. Timko, J. C. Dudda, T. E. West, C. B. Wilson, A. M. Hajjar, and S. J. Skerrett
Administration of a Synthetic TLR4 Agonist Protects Mice from Pneumonic Tularemia
J. Immunol., June 1, 2008; 180(11): 7574 - 7581.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. Tebow, D. L. Sherrill, I. C. Lohman, D. A. Stern, A. L. Wright, F. D. Martinez, M. Halonen, and S. Guerra
Effects of Parental Smoking on Interferon {gamma} Production in Children
Pediatrics, June 1, 2008; 121(6): e1563 - e1569.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
L. Liang and B. Roizman
Expression of Gamma Interferon-Dependent Genes Is Blocked Independently by Virion Host Shutoff RNase and by US3 Protein Kinase
J. Virol., May 15, 2008; 82(10): 4688 - 4696.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Feld, V. M. Shpacovitch, C. Ehrhardt, C. Kerkhoff, M. D. Hollenberg, N. Vergnolle, S. Ludwig, and M. Steinhoff
Agonists of Proteinase-Activated Receptor-2 Enhance IFN-{gamma}-Inducible Effects on Human Monocytes: Role in Influenza A Infection
J. Immunol., May 15, 2008; 180(10): 6903 - 6910.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. Miu, N. H. Hunt, and H. J. Ball
Predominance of Interferon-Related Responses in the Brain during Murine Malaria, as Identified by Microarray Analysis
Infect. Immun., May 1, 2008; 76(5): 1812 - 1824.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
K. M. Page, D. Chaudhary, S. J. Goldman, and M. T. Kasaian
Natural killer cells from protein kinase C {theta}-/- mice stimulated with interleukin-12 are deficient in production of interferon-{gamma}
J. Leukoc. Biol., May 1, 2008; 83(5): 1267 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. D. Kalliolias and L. B. Ivashkiv
IL-27 Activates Human Monocytes via STAT1 and Suppresses IL-10 Production but the Inflammatory Functions of IL-27 Are Abrogated by TLRs and p38
J. Immunol., May 1, 2008; 180(9): 6325 - 6333.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
I. Jutras, M. Houde, N. Currier, J. Boulais, S. Duclos, S. LaBoissiere, E. Bonneil, P. Kearney, P. Thibault, E. Paramithiotis, et al.
Modulation of the Phagosome Proteome by Interferon-{gamma}
Mol. Cell. Proteomics, April 1, 2008; 7(4): 697 - 715.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
N. M. Iovine, S. Pursnani, A. Voldman, G. Wasserman, M. J. Blaser, and Y. Weinrauch
Reactive Nitrogen Species Contribute to Innate Host Defense against Campylobacter jejuni
Infect. Immun., March 1, 2008; 76(3): 986 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. M. Rosenberger, A. E. Clark, P. M. Treuting, C. D. Johnson, and A. Aderem
ATF3 regulates MCMV infection in mice by modulating IFN-{gamma} expression in natural killer cells
PNAS, February 19, 2008; 105(7): 2544 - 2549.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Peng, J. Zhu, Y. Hwangbo, L. Corey, and R. E. Bumgarner
Independent and Cooperative Antiviral Actions of Beta Interferon and Gamma Interferon against Herpes Simplex Virus Replication in Primary Human Fibroblasts
J. Virol., February 15, 2008; 82(4): 1934 - 1945.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Dummer, A. Hauschild, J. C. Becker, J.-J. Grob, D. Schadendorf, V. Tebbs, J. Skalsky, K. C. Kaehler, S. Moosbauer, R. Clark, et al.
An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma
Clin. Cancer Res., February 1, 2008; 14(3): 856 - 864.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Barber, T. Zhang, and C. L. Sentman
Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer
J. Immunol., January 1, 2008; 180(1): 72 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
S. A. M. Martin, J. B. Taggart, P. Seear, J. E. Bron, R. Talbot, A. J. Teale, G. E. Sweeney, B. Hoyheim, D. F. Houlihan, D. R. Tocher, et al.
Interferon type I and type II responses in an Atlantic salmon (Salmo salar) SHK-1 cell line by the salmon TRAITS/SGP microarray
Physiol Genomics, December 19, 2007; 32(1): 33 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
H. Beekhuizen and J. S. van de Gevel
Gamma Interferon Confers Resistance to Infection with Staphylococcus aureus in Human Vascular Endothelial Cells by Cooperative Proinflammatory and Enhanced Intrinsic Antibacterial Activities
Infect. Immun., December 1, 2007; 75(12): 5615 - 5626.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
M. A. Smith, J. S. Moylan, J. D. Smith, W. Li, and M. B. Reid
IFN-{gamma} does not mimic the catabolic effects of TNF-{alpha}
Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1947 - C1952.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Zhang, A. Barber, and C. L. Sentman
Chimeric NKG2D Modified T Cells Inhibit Systemic T-Cell Lymphoma Growth in a Manner Involving Multiple Cytokines and Cytotoxic Pathways
Cancer Res., November 15, 2007; 67(22): 11029 - 11036.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. C. Henry, X. Daniell, M. Indaram, J. F. Whitesides, G. D. Sempowski, D. Howell, T. Oliver, and G. A. Taylor
Impaired Macrophage Function Underscores Susceptibility to Salmonella in Mice Lacking Irgm1 (LRG-47)
J. Immunol., November 15, 2007; 179(10): 6963 - 6972.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
R. Trotta, D. Ciarlariello, J. D. Col, J. Allard II, P. Neviani, R. Santhanam, H. Mao, B. Becknell, J. Yu, A. K. Ferketich, et al.
The PP2A inhibitor SET regulates natural killer cell IFN-{gamma} production
J. Exp. Med., October 1, 2007; 204(10): 2397 - 2405.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Schroder, M. Spille, A. Pilz, J. Lattin, K. A. Bode, K. M. Irvine, A. D. Burrows, T. Ravasi, H. Weighardt, K. J. Stacey, et al.
Differential Effects of CpG DNA on IFN-beta Induction and STAT1 Activation in Murine Macrophages versus Dendritic Cells: Alternatively Activated STAT1 Negatively Regulates TLR Signaling in Macrophages
J. Immunol., September 15, 2007; 179(6): 3495 - 3503.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. G. Binker, D. Y. Zhao, S. J. Y. Pang, and R. E. Harrison
Cytoplasmic Linker Protein-170 Enhances Spreading and Phagocytosis in Activated Macrophages by Stabilizing Microtubules
J. Immunol., September 15, 2007; 179(6): 3780 - 3791.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. L. Rose
Interferon-{gamma} and Intimal Hyperplasia
Circ. Res., September 14, 2007; 101(6): 542 - 544.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
M. Koga, H. Kai, H. Yasukawa, T. Yamamoto, Y. Kawai, S. Kato, K. Kusaba, M. Kai, K. Egashira, Y. Kataoka, et al.
Inhibition of Progression and Stabilization of Plaques by Postnatal Interferon-{gamma} Function Blocking in ApoE-Knockout Mice
Circ. Res., August 17, 2007; 101(4): 348 - 356.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. J. Cameron, L. Ran, L. Xu, A. Danesh, J. F. Bermejo-Martin, C. M. Cameron, M. P. Muller, W. L. Gold, S. E. Richardson, S. M. Poutanen, et al.
Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome
J. Virol., August 15, 2007; 81(16): 8692 - 8706.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Tewari, Y. Nakayama, and M. Suresh
Role of Direct Effects of IFN-{gamma} on T Cells in the Regulation of CD8 T Cell Homeostasis
J. Immunol., August 15, 2007; 179(4): 2115 - 2125.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Tokumasa, A. Suto, S.-i. Kagami, S. Furuta, K. Hirose, N. Watanabe, Y. Saito, K. Shimoda, I. Iwamoto, and H. Nakajima
Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-{gamma} production and the induction of Th1 cell differentiation
Blood, July 15, 2007; 110(2): 553 - 560.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. J. Prasanna, B. Saha, and D. Nandi
Involvement of oxidative and nitrosative stress in modulation of gene expression and functional responses by IFN{gamma}
Int. Immunol., July 2, 2007; (2007) dxm058v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. Lattin, D. A. Zidar, K. Schroder, S. Kellie, D. A. Hume, and M. J. Sweet
G-protein-coupled receptor expression, function, and signaling in macrophages
J. Leukoc. Biol., July 1, 2007; 82(1): 16 - 32.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Neff-LaFord, S. Teske, T. P. Bushnell, and B. P. Lawrence
Aryl Hydrocarbon Receptor Activation during Influenza Virus Infection Unveils a Novel Pathway of IFN-{gamma} Production by Phagocytic Cells
J. Immunol., July 1, 2007; 179(1): 247 - 255.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. M. Brown, Q. Xu, N. Okhubo, M. P. Vitek, and C. A. Colton
Androgen-Mediated Immune Function Is Altered by the Apolipoprotein E Gene
Endocrinology, July 1, 2007; 148(7): 3383 - 3390.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. A. Stout, K. Melendez, J. Seagrave, M. J. Holtzman, B. Wilson, J. Xiang, and Y. Tesfaigzi
STAT1 Activation Causes Translocation of Bax to the Endoplasmic Reticulum during the Resolution of Airway Mucous Cell Hyperplasia by IFN-{gamma}
J. Immunol., June 15, 2007; 178(12): 8107 - 8116.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
K. Schroder, M. Lichtinger, K. M. Irvine, K. Brion, A. Trieu, I. L. Ross, T. Ravasi, K. J. Stacey, M. Rehli, D. A. Hume, et al.
PU.1 and ICSBP control constitutive and IFN-{gamma}-regulated Tlr9 gene expression in mouse macrophages
J. Leukoc. Biol., June 1, 2007; 81(6): 1577 - 1590.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Hayashi, Y. Ishida, A. Kimura, Y. Iwakura, N. Mukaida, and T. Kondo
IFN-{gamma} Protects Cerulein-Induced Acute Pancreatitis by Repressing NF-{kappa}B Activation
J. Immunol., June 1, 2007; 178(11): 7385 - 7394.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Lissat, T. Vraetz, M. Tsokos, R. Klein, M. Braun, N. Koutelia, P. Fisch, M. E. Romero, L. Long, P. Noellke, et al.
Interferon-{gamma} Sensitizes Resistant Ewing's Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity
Am. J. Pathol., June 1, 2007; 170(6): 1917 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. M. Ripoll, K. M. Irvine, T. Ravasi, M. J. Sweet, and D. A. Hume
Gpnmb Is Induced in Macrophages by IFN-{gamma} and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses
J. Immunol., May 15, 2007; 178(10): 6557 - 6566.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
I. K. Mullarky, F. M. Szaba, L. W. Kummer, L. B. Wilhelm, M. A. Parent, L. L. Johnson, and S. T. Smiley
Gamma Interferon Suppresses Erythropoiesis via Interleukin-15
Infect. Immun., May 1, 2007; 75(5): 2630 - 2633.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Li, L. Huang, S.-s. J. Sung, P. I. Lobo, M. G. Brown, R. K. Gregg, V. H. Engelhard, and M. D. Okusa
NKT Cell Activation Mediates Neutrophil IFN-{gamma} Production and Renal Ischemia-Reperfusion Injury
J. Immunol., May 1, 2007; 178(9): 5899 - 5911.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. M.A. Rogers, M. Thomas, L. Galligan, T. R. Wilson, W. L. Allen, H. Sakai, P. G. Johnston, and D. B. Longley
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells
Mol. Cancer Ther., May 1, 2007; 6(5): 1544 - 1551.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Woszczek, L.-Y. Chen, S. Nagineni, S. Alsaaty, A. Harry, C. Logun, R. Pawliczak, and J. H. Shelhamer
IFN-{gamma} Induces Cysteinyl Leukotriene Receptor 2 Expression and Enhances the Responsiveness of Human Endothelial Cells to Cysteinyl Leukotrienes
J. Immunol., April 15, 2007; 178(8): 5262 - 5270.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
K. Kusaba, H. Kai, M. Koga, N. Takayama, A. Ikeda, H. Yasukawa, Y. Seki, K. Egashira, and T. Imaizumi
Inhibition of Intrinsic Interferon-{gamma} Function Prevents Neointima Formation After Balloon Injury
Hypertension, April 1, 2007; 49(4): 909 - 915.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Hurgin, D. Novick, A. Werman, C. A. Dinarello, and M. Rubinstein
Antiviral and immunoregulatory activities of IFN-{gamma} depend on constitutively expressed IL-1{alpha}
PNAS, March 20, 2007; 104(12): 5044 - 5049.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Zhang, S. Byrne, N. Liu, Y. Wang, A. Oxenius, and P. G. Ashton-Rickardt
Differential Survival of Cytotoxic T Cells and Memory Cell Precursors
J. Immunol., March 15, 2007; 178(6): 3483 - 3491.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Becknell, T. L. Hughes, A. G. Freud, B. W. Blaser, J. Yu, R. Trotta, H. C. Mao, M. L. Caligiuri de Jesus, M. Alghothani, D. M. Benson Jr, et al.
Hlx homeobox transcription factor negatively regulates interferon-{gamma} production in monokine-activated natural killer cells
Blood, March 15, 2007; 109(6): 2481 - 2487.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. J. Glomski, J.-P. Corre, M. Mock, and P. L. Goossens
Cutting Edge: IFN-{gamma}-Producing CD4 T Lymphocytes Mediate Spore-Induced Immunity to Capsulated Bacillus anthracis
J. Immunol., March 1, 2007; 178(5): 2646 - 2650.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Mancuso, A. Midiri, C. Biondo, C. Beninati, S. Zummo, R. Galbo, F. Tomasello, M. Gambuzza, G. Macri, A. Ruggeri, et al.
Type I IFN Signaling Is Crucial for Host Resistance against Different Species of Pathogenic Bacteria
J. Immunol., March 1, 2007; 178(5): 3126 - 3133.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Ramsauer, M. Farlik, G. Zupkovitz, C. Seiser, A. Kroger, H. Hauser, and T. Decker
Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-{gamma}-inducible gbp2 gene
PNAS, February 20, 2007; 104(8): 2849 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Vremec, M. O'Keeffe, H. Hochrein, M. Fuchsberger, I. Caminschi, M. Lahoud, and K. Shortman
Production of interferons by dendritic cells, plasmacytoid cells, natural killer cells, and interferon-producing killer dendritic cells
Blood, February 1, 2007; 109(3): 1165 - 1173.